Inborn errors of immunity, also referred to as primary immunodeficiencies, manifest as increased susceptibility to infectious diseases, autoimmunity, autoinflammatory diseases, allergy, and/or malignancy. These conditions are caused by monogenic germline mutations that result in loss of expression, loss-of-function (LOF; amorphic/hypomorphic), or gain-of-function (GOF; hypermorphic) of the encoded protein \[[@CR1], [@CR2]\]. Heterozygous lesions may underlie autosomal dominant traits by GOF, haploinsufficiency, or negative dominance. Biallelic lesions typically cause autosomal recessive traits by LOF of the encoded protein (rarely GOF), while X-linked recessive traits arise from LOF of genes on the X chromosome, either in the hemizygous state in males or in the homozygous state in females. Rare X-linked dominant traits can also arise from LOF or GOF variants. This results in aberrant immunity due to the critical roles of these proteins in the development, maintenance and function of cells of the immune system, or cells other than leukocytes that contribute to immunity, during homeostasis and in response to external (e.g., infectious agents or environmental antigens) and internal (e.g., cytokines, self-antigens and cancer cells) stimuli \[[@CR3]--[@CR5]\]. Inborn errors of immunity were traditionally considered to be rare diseases, affecting \~ 1 in 10,000 to 1 in 50,000 births. However, with ongoing discovery of novel inborn errors of immunity (Fig. [1a](#Fig1){ref-type="fig"}) and improved definition of clinical phenotypes \[[@CR6]--[@CR8]\], the collective prevalence of these conditions is more likely to be at least 1/1000--1/5000 \[[@CR9]\]. Indeed, more common inborn errors have recently been described \[[@CR10]\]. Regardless of their exact incidence and prevalence, inborn errors of immunity represent an unprecedented model to link defined monogenic defects with clinical phenotypes of immune dysregulation, in a broad sense of the term. As a committee, we are aware that human immunity involves cells other than circulating or tissue leukocytes and that it can be scaled up from the immune system to the whole organism. Inborn errors of immunity have unequivocally revealed non-redundant roles of single genes and their products in immune function \[[@CR3], [@CR4], [@CR6]--[@CR8]\], formed the basis of improved mechanism-based therapies for the immunopathology underlying many diseases \[[@CR8], [@CR11]\], established immunological paradigms representing the foundations of basic, clinical and translational immunology \[[@CR3]--[@CR5], [@CR9], [@CR12]--[@CR14]\], and provided insights into the molecular pathogenesis of more common diseases \[[@CR9], [@CR15]\]. Clear examples of these include:The initial description by Bruton of X-linked agammaglobulinemia (XLA) and the ability to treat this condition with antibody replacement therapy (the mainstay treatment for antibody deficiency diseases such as CVID) \[[@CR16]\]The discovery of mutations in *BTK* \[[@CR12]\] and the subsequent development of BTK-inhibitors such as ibrutinib for the treatment of B cell malignancies \[[@CR14]\]Progressive CD4 T cell deficiency explains opportunistic infections secondary to HIV infection \[[@CR9]\].Fig. 1Rate of discovery of novel inborn errors of immunity: 1983--2019. **a** The number of genetic defects underlying monogenic immune disorders as reported by the IUIS/WHO committee in the indicated year. **b** The number of pathogenic gene variants listed in each table by the IUIS committee. Report published in 2017, and the number of new genes for each table contained in this report (red bars). The numbers in each column correspond to the number of genes reported in the 2017 IUIS update (blue bars) \[[@CR1], [@CR2]\], the number of new genes for each table contained in this report (red bars), and the total number of genes for each table. Note: only data for Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}, [4](#Tab4){ref-type="table"}, [5](#Tab5){ref-type="table"}, [6](#Tab6){ref-type="table"}, [7](#Tab7){ref-type="table"}, and [8](#Tab8){ref-type="table"} are shown, because Table [9](#Tab9){ref-type="table"} (bone marrow failure) is a new addition to the current report.

Thus, the study of inborn errors of immunity has provided profound advances in the practice of precision molecular medicine.

Since the early 1950s, when XLA was one of the first primary immune deficiencies to be described \[[@CR16]\], clinical immunology has leveraged advances in the development of new methods to expedite the identification of defects of the immune system and the cellular, molecular, and genetic aberrations underlying these conditions. Indeed, the completion of the Human Genome Project in the early 2000s, coupled with rapid developments in next generation DNA sequencing (NGS) technologies, enabled the application of cost-effective and time-efficient sequencing of targeted gene panels, whole exomes, or whole genomes to cohorts of patients suspected of having a monogenic explanation for their disease. These platforms have led to a quantum leap in the identification and diagnosis of previously undefined genetically determined defects of the immune system (Fig. [1a, b](#Fig1){ref-type="fig"}; \[[@CR6]--[@CR8]\]).

The International Union of Immunological Societies Expert Committee of Inborn Errors of Immunity comprises pediatric and adult clinical immunologists, clinician/scientists and researchers in basic immunology from across the globe (<https://iuis.org/committees/iei/>). A major objective and responsibility of the committee is to provide the clinical and research communities with an update of genetic causes of immune deficiency and dysregulation. The committee has existed since 1970 and has published an updated report approximately every 2 years to inform the field of these advances (Fig. [1a](#Fig1){ref-type="fig"}). In March 2019, the committee met in New York to discuss and debate the inclusion of genetic variants published over the preceding 2 years (since June 2017) \[[@CR1], [@CR2]\], as well as gene mutations that had appeared in the literature earlier but, based on newly available evidence, were now substantiated (Fig. [1b](#Fig1){ref-type="fig"}).

Rather than simply including every gene variant reported, the committee applies very stringent criteria such that only those genes with convincing evidence of disease pathogenicity are classified as causes of novel inborn errors of immunity \[[@CR17]\]. The Committee makes informed judgments for including new genetic causes of immunological conditions based on what we believe is most useful for practitioners caring for patients. Our current, and continuously evolving, practice is that criteria for inclusion can be met by several ways, for instance peer-reviewed publication of (1) multiple cases from unrelated kindreds, including detailed immunologic data, or (2) very few cases, or even a single case (see below), for whom compelling mechanistic/pathogenic data is also provided, generally from parallel studies in an animal or cell culture model.

Herein, we provide this latest update. The inborn errors of immunity are listed in 10 tables: Combined immunodeficiencies (Table [1](#Tab1){ref-type="table"}), Combined immunodeficiencies with syndromic features (Table [2](#Tab2){ref-type="table"}), Predominantly antibody deficiencies (Table [3](#Tab3){ref-type="table"}), Diseases of immune dysregulation (Table [4](#Tab4){ref-type="table"}), Congenital defects of phagocytes (Table [5](#Tab5){ref-type="table"}), Defects in intrinsic and innate immunity (Table [6](#Tab6){ref-type="table"}), Autoinflammatory diseases (Table [7](#Tab7){ref-type="table"}), Complement deficiencies (Table [8](#Tab8){ref-type="table"}), and Phenocopies of inborn errors of immunity (Table [10](#Tab10){ref-type="table"}) (Fig. [1b](#Fig1){ref-type="fig"}). Since the last update (published January 2018) \[[@CR1], [@CR2]\], we have added a new table to consolidate genes that cause bone marrow failure (Table [9](#Tab9){ref-type="table"}). Our division into phenotypes does not imply that the presentation is homogeneous. Rather, we recognize that substantial phenotypic and clinical heterogeneity exists within groups of patients with mutations in the same gene and even between individuals from the same pedigree with the identical gene mutation. To simplify the classification, each disorder has been listed only once, although distinct disorders due to mutations in the same gene, but with different modes of inheritance and pathogenic mechanisms are listed individually. Thus, several genes appear more than once in this update (some examples are listed below). Sub-divisions within each table segregate groups of disorders into coherent phenotypic sets. OMIM numbers are also provided within each table. If a OMIM number has not yet been issued for a particular genetic condition, then the number provided generally refers to the OMIM for that gene. Beneath each table, the new disorders added to this update are highlighted for easy reference.Table 1Immunodeficiencies affecting cellular and humoral immunityDiseaseGenetic defectInheritanceOMIMT cellsB cellsIgAssociated features1. T-B+ severe combined immune deficiency (SCID)  γc deficiency (common gamma chain SCID, CD132 deficiency)*IL2RG*XL308380Very lowNormal to highLowLow NK  JAK3 deficiency*JAK3*AR600173Very lowNormal to highLowLow NK  IL7Rα deficiency*IL7R*AR146661Very lowNormal to highLowNormal NK  CD45 deficiency*PTPRC*AR151460Very lowNormalLowNormal γ/δ Τ cells  CD3δ deficiency*CD3D*AR186790Very lowNormalLowNormal NK, no γ/δ T cells  CD3ε deficiency*CD3E*AR186830Very lowNormalLowNormal NK, no γ/δ T cells  CD3ζ deficiency*CD3Z*AR186780Very lowNormalLowNormal NK, no γ/δ T cells  Coronin-1A deficiency*CORO1A*AR605000Very lowNormalLowDetectable thymus  LAT deficiency*LAT*AR602354Normal to lowNormal to lowHighTypical SCID or combined immunodeficiency, the latter with adenopathy, splenomegaly, recurrent infections, autoimmunity2. T-B- SCID  RAG deficiency*RAG1RAG2*AR179615179616Very lowVery lowDecreasedNormal NK cell number, but increased risk of graft rejection, possibly due to activated NK cells  DCLRE1C (Artemis) deficiency*DCLRE1C*AR605988Very lowVery lowDecreasedNormal NK cell number, but increased risk of graft rejection, possibly due to activated NK cells, radiation sensitivity  DNA PKcs deficiency*PRKDC*AR615966Very lowVery lowVariableNormal NK, radiation sensitivity, microcephaly  Cernunnos/XLF deficiency*NHEJ1*AR611290Very lowVery lowDecreasedNormal NK, radiation sensitivity, microcephaly  DNA ligase IV deficiency*LIG4*AR601837Very lowVery lowDecreasedNormal NK, radiation sensitivity, microcephaly  Adenosine deaminase (ADA) deficiency*ADA*AR608958Very lowLow, decreasingLow, decreasingLow NK, bone defects, may have pulmonary alveolar proteinosis, cognitive defects  AK2 defect*AK2*AR[103020]{.ul}Very lowVery LowDecreasedReticular dysgenesis with neutropenia; deafness  Activated RAC2 defect*RAC2*AD GOF602049Very lowVery LowLow, poor specific antibody responsesRecurrent bacterial and viral infections, lymphoproliferation; neutropenia3. Combined immunodeficiency (CID), generally less profound than SCID  CD40 ligand (CD154) deficiency*CD40LG*XL[308230]{.ul}Normal to lowsIgM^+^IgD^+^ naïve B cells present; IgG^+^, IgA^+^, IgE^+^ memory B cells absentIgM normal or high, other Ig isotypes lowSevere and opportunistic infections, idiopathic neutropenia; hepatitis and cholangitis, *Cryptosporidiu*m infections, cholangiocarcinoma; autoimmune blood cytopenias; peripheral neuroectodermal tumors  CD40 deficiency*CD40*AR[606843]{.ul}NormalNeutropenia, opportunistic infections, gastrointestinal and biliary tract and liver disease, *Cryptosporidium* infections  ICOS deficiency*ICOS*AR604558NormalNormalLowRecurrent infections, autoimmunity, gastroenteritis, granulomas  ICOSL deficiency*ICOSLG*AR[605717]{.ul}LowLowLowRecurrent bacterial and viral infections, neutropenia  CD3γ deficiency*CD3G*AR186740Normal number, but low TCR expressionNormalNormalImmune deficiency and autoimmunity of variable severity  CD8 deficiency*CD8A*AR186910Absent CD8, Normal CD4NormalNormalRecurrent infections, may be asymptomatic  ZAP-70 deficiency (ZAP70 LOF)*ZAP70*AR269840Low CD8 number, normal CD4 number but with poor functionNormalNormalMay have immune dysregulation, autoimmunity  ZAP-70 combined hypomorphic and activating mutations*ZAP70*AR (LOF/GOF)617006Decreased CD8, normal or decreased CD4 cellsNormal or decreasedNormal IgA, low IgM, low/normal IgG; protective Ab responses to vaccinesSevere autoimmunity (bullous pemphigoid, inflammatory colitis  MHC class I deficiency*TAP1*AR170260Low CD8, normal CD4, absent MHC I on lymphocytesNormalNormalVasculitis, pyoderma gangrenosum*TAP2*AR170261*TAPBP*AR601962*B2M*AR109700Sinopulmonary infections, cutaneous granulomas. Absent β2m associated proteins MHC-I, CD1a, CD1b, and CD1c  MHC class II deficiency group A, B, C, D*CIITA*AR600005Low CD4+ T cells, reduced MHC II expression on lymphocytesNormalNormal to lowFailure to thrive, respiratory and gastrointestinal infections, liver/biliary tract disease*RFXANK*AR603200*RFX5*AR601863*RFXAP*AR601861  IKAROS deficiency*IKZF1*AD DN[603023]{.ul}no memory T cellsno memory B cellsLow Ig,recurrent sinopulmonary infections, pneumocystis early CID onset  DOCK8 deficiency*DOCK8*AR243700T cell lymphopenia, reduced naïve CD8 T cells, increased exhausted CD8+ T~EM~ cells, reduced MAIT, NKT cells, increased γδ T cells; poor proliferation; few Treg with poor functionincreased total B cells, reduced memory B cells Poor peripheral B cell tolerance.Low IgM, normal/high IgG and IgA, very high IgE, poor antibody responsesLow NK cells with poor function. Eosinophilia, recurrent infections, cutaneous viral, fungal and staphylococcal infections, severe atopy/allergic disease, cancer diathesis  DOCK2 deficiency*DOCK2*AR603122LowNormalIgG normal or low, poor antibody responsesEarly invasive herpes viral, bacterial infections, Normal NK cell number, but defective function. Poor interferon responses in hematopoietic and non-hematopoietic cells  Polymerase and deficiency*POLD1POLD2*AR174761600815Low CD4 T cellsLow B cells but normal maturationLow igGRecurrent respiratory tract infections, skin infections, warts and molluscum, short stature, intellectual disability  RHOH deficiency*RHOH*AR602037Normal, few naïve T cells, restricted repertoire, poor proliferation to CD3NormalNormalHPV infection, lung granulomas, molluscum contagiosum, lymphoma  STK4 deficiency*STK4*AR614868CD4 lymphopenia, reduced naïve T cells, increased TEM and TEMRA cells, poor proliferationReduced memory B cellsReduced IgM, increased IgG, IgA, IgE; impaired Ab responsesIntermittent neutropenia, bacterial, viral (HPV, EBV, molluscum), candidal infections, lymphoproliferation, autoimmune cytopenias, lymphoma, congenital heart disease  TCRα deficiency*TRAC*AR615387Absent TCRαβ except for a minor CD3-dim TCRαβ population; most T cells γδ; poor proliferationNormalNormalRecurrent viral, bacterial, fungal infections, immune dysregulation and autoimmunity, diarrhea  LCK deficiency*LCK*AR615758Low CD4^+^, low Treg, restricted T cell repertoire, poor TCR signalingNormalNormal IgG and IgA, high IgMRecurrent infections, immune dysregulation, autoimmunity  ITK deficiency*ITK*AR186973Progressive CD4 T cell lymphopenia; reduced T cell activationNormalNormal to low serum IgEBV associated B cell lymphoproliferation, lymphoma, immune dysregulation  MALT1 deficiency*MALT1*AR615468Normal number, poor proliferationNormalNormal levels, poor specific antibody responseBacterial, fungal and viral infections  CARD11 deficiency*CARD11*AR LOF615206Normal number, predominantly naïve T cells, poor proliferationNormal, transitional B cell predominanceAbsent/low*Pneumocystis jirovecii* pneumonia, bacterial and viral infections  BCL10 deficiency*BCL10*AR616098Normal number, few memory T and Treg cells, poor antigen and anti-CD3 proliferationNormal number, decreased memory and switched B cellsLowRecurrent bacterial and viral infections, candidiasis, gastroenteritis  IL-21 deficiency*IL21*AR615767Normal number, normal/low functionLow, decreased memory and switched B cellsHypogammaglobulinemia, poor specific antibody responses; increased IgESevere early onset colitis, recurrent sinopulmonary infections  IL-21R deficiency*IL21R*AR615207Normal number, low cytokine production, poor antigen proliferationNormal, decreased memory and switched B cellsRecurrent infections, *Pneumocystis jiroveci*, *Cryptosporidium* infections, liver disease  OX40 deficiency*TNFRSF4*AR615593Normal numbers, low antigen specific memory CD4+Normal numbers, low memory B cellsNormalImpaired immunity to HHV8, Kaposi's sarcoma  IKBKB deficiency*IKBKB*AR615592Normal number, absent Treg and γ/δ T cells, impaired TCR activationNormal number, poor functionLowRecurrent bacterial, viral, fungal infections, opportunistic infections  NIK deficiency*MAP 3 K14*AR604655Normal number, poor proliferation to antigenLow, low switched memory B cellsLow Ig'sLow NK number and function, recurrent bacterial, viral and *Cryptosporidium* infections  RelB deficiency*RELB*AR604758Normal number, poor diversity, reduced proliferation to mitogens; no response to AgMarked increase in B cell numberNormal Ig levels but Impaired specific antibody responsesRecurrent infections  RelA haploinsufficiency*RELA*AD618287Normal/increasedNormalNormalChronic mucocutaneous ulceration, Impaired NFkB activation; reduced production of inflammatory cytokines  Moesin deficiency*MSN*XL300988Normal number, defective migration, proliferationLow numberLow Ig's over timeRecurrent infections with bacteria, varicella, neutropenia  TFRC deficiency*TFRC*AR616740Normal number, poor proliferationNormal number, low memory B cellsLowRecurrent infections, neutropenia, thrombocytopenia  c-Rel deficiency*REL*AR[164910]{.ul}Normal, decreased memory CD4, poor proliferationLow, mostly naïve; few switched memory B cells, impaired proliferationLow, poor specific antibody responsesRecurrent infections with bacteria, mycobacteria, salmonella and opportunistic organisms. Defective innate immunity  FCHO1 deficiency*FCHO1*AR[613437]{.ul}Low, poor proliferationNormal numberNormalRecurrent infections (viral, mycobacteria, bacterial, fungal), lymphoproliferation, failure to thrive, increased activation-induced T cell death, defective clathrin-mediated endocytosisSCID/CID spectrum: Infants with SCID who have maternal T cell engraftment may have T cells in normal numbers that do not function normally; these cells may cause autoimmune cytopenias or graft versus host disease. Hypomorphic mutations in several of the genes that cause SCID may result in Omenn syndrome (OS), or "leaky" SCID, or still less profound combined immunodeficiency (CID) phenotypes. Both OS and leaky SCID can be associated with \> 300 autologous T cells/μL of peripheral blood and reduced, rather than absent, proliferative responses when compared with typical SCID caused by null mutations. A spectrum of clinical findings including typical SCID, OS, leaky SCID, CID, granulomas with T lymphopenia, autoimmunity and CD4 T lymphopenia can be found in an allelic series of *RAG1/2* and other SCID-associated genes. There can be clinical overlap between some genes listed here and those listed in Table [7](#Tab7){ref-type="table"}Total number of disorders in Table 1: 50Total number of mutant genes: 58New inborn errors of immunity: 8; New inborn errors of immunity: 8; *RAC2* GOF \[[@CR18]--[@CR21]\]; *ICOSLG* \[[@CR22]\]; AD DN *IKZF1* \[[@CR23]\]; *POLD1* \[[@CR24], [@CR25]\]; *POLD2* \[[@CR24]\]; *RELA* \[[@CR26], [@CR27]\]; *REL* \[[@CR28]\]; *FCHO1* \[[@CR29]\]*SCID* severe combined immunodeficiency, *CID* combined immunodeficiency, *EBV* Epstein-Barr virus, *MHC* major histocompatibility complex, *HPV* human papillomavirus, *Treg* T regulatory cell, *XL* X-linked inheritance, *AR* autosomal recessive inheritance, *AD* autosomal dominant inheritance, *LOF* loss-of-function, *GOF* gain-of-functionTable 2Combined immunodeficiencies with associated or syndromic featuresDiseaseGenetic defectInheritanceOMIMT cellsB cellsIgAssociated features1. Immunodeficiency with congenital thrombocytopenia  Wiskott-Aldrich syndrome (WAS LOF)*WAS*XL300392Progressive decrease in numbers, abnormal lymphocyte responses to anti-CD3Normal numbersLow IgM and antibody responses to polysaccharides, often high IgA and IgEThrombocytopenia with small platelets, eczema, recurrent bacterial/viral infections, bloody diarrhea, lymphoma, autoimmune disease, IgA- nephropathy. Patients with XL-thrombocytopenia have later onset of complications and more favourable life expectancy but eventually develop similar complications as observed in WAS  WIP deficiency*WIPF1*AR602357Reduced, defective lymphocyte responses to anti-CD3Normal or lowNormal, except for high IgEThrombocytopenia with or without small platelets, recurrent bacterial and viral infections, eczema, bloody diarrhea; WAS protein absent  Arp2/3-mediated filament branching defect*ARPC1B*AR604223NormalNormal numbersNormal except for high IgA and IgEMild thrombocytopenia with normal sized platelets, recurrent invasive infections; colitis, vasculitis, autoantibodies (ANA, ANCA), eosinophilia; defective Arp2/3 filament branching2. DNA repair defects other than those listed in Table [1](#Tab1){ref-type="table"}  Ataxia-telangiectasia*ATM*AR607585Progressive decrease, poor proliferation to mitogens; may have low TRECs and T cells by newborn screening (NBS)NormalOften low IgA, IgE and IgG subclasses, increased IgM monomers; antibodies variably decreasedAtaxia, telangiectasia especially of sclerae; pulmonary infections; lymphoreticular and other malignancies; increased alpha fetoprotein; increased radiosensitivity, chromosomal instability and chromosomal translocations  Nijmegen breakage syndrome*NBS1*AR602667Progressive decrease; may have low TRECs and T cells by NBSVariably reducedOften low IgA, IgE, and IgG subclasses, increased IgM; antibodies variably decreasedMicrocephaly, dysmorphic facies; lymphomas and solid tumors; increased radiosensitivity;, chromosomal instability  Bloom syndrome*BLM*AR604610NormalNormalLowShort stature, dysmorphic facies sun-sensitive erythema; marrow failure; leukemia, lymphoma; chromosomal instability  Immunodeficiency with centromeric instability and facial anomalies (ICF types 1, 2, 3, 4)*DNMT3B*AR602900Decreased or normal, responses to PHA may be decreasedDecreased or normalHypogammaglobulinemia or agammaglobulinemia, variable antibody deficiencyFacial dysmorphic features, developmental delay, macroglossia; bacterial/opportunistic infections; malabsorption; cytopenias; malignancies; multiradial configurations of chromosomes 1, 9, 16*ZBTB24*AR614064Decreased or normalFacial dysmorphic features, macroglossia; bacterial/opportunistic infections; malabsorption; cytopenias; malignancies; multiradial configurations of chromosomes 1, 9, 16*CDCA7*AR609937Decreased or normal; responses to PHA may be decreased*HELLS*AR603946Decreased or normal  PMS2 deficiency*PMS2*AR600259NormalLow B cells, switched and non-switchedLow IgG and IgA, high IgM, abnormal antibody responsesRecurrent infections; café-au-lait spots; lymphoma, colorectal carcinoma, brain tumors  RNF168 deficiency (Radiosensitivity, Immune Deficiency, Dysmorphic features, Learning difficulties \[RIDDLE\] syndrome)*RNF168*AR612688NormalNormalLow IgG or IgAShort stature, mild defect of motor control to ataxia; normal intelligence to learning difficulties; mild facial dysmorphism to microcephaly; increased radiosensitivity  MCM4 deficiency*MCM4*AR602638NormalNormalNormalNK cells: low number and function; viral infections (EBV, HSV, VZV); short stature; B cell lymphoma; adrenal failure  X-linked reticulate pigmentary disorder (POLA1 deficiency)*POLA1*XL301220Not assessedNot assessedNot assessedHyperpigmentation, characteristic facies, lung and GI involvement  POLE1 (Polymerase ε subunit 1) deficiency (FILS syndrome)*POLE1*AR174762Normal; decreased T cell proliferationLow memory B cellsLow IgG2 and IgM, lack of antibody to PPSRecurrent respiratory infections, meningitis; facial dysmorphism, livido, short stature  POLE2 (Polymerase ε subunit 2) deficiency*POLE2*AR602670Lymphopenia, lack of TRECS at NBS, absent proliferation in response to antigensVery lowHypogammaglobulinemiaRecurrent infections, disseminated BCG infections; autoimmunity (type 1 diabetes), hypothyroidism, facial dysmorphism  Ligase I deficiency*LIG1*AR126391Lymphopenia, increased γδ T cells, decreased mitogen responseNormalHypogammaglobulinemia, Reduced antibody responsesRecurrent bacterial and viral infections; growth retardation; sun sensitivity, radiation sensitivity; macrocytic red blood cells  NSMCE3 deficiency*NSMCE3*AR608243Decreased number, poor responses to mitogens and antigensNormalNormal IgG, IgA, normal to elevated IgM; decreased antibody responses to PPSSevere lung disease (possibly viral); thymic hypoplasia; chromosomal breakage, radiation sensitivity  ERCC6L2 (Hebo deficiency)*ERCC6L2*AR615667LymphopeniaLowNormalFacial dysmorphism, microcephaly; bone marrow failure  GINS1 deficiency*GINS1*AR610608Low or normalLow or normalHigh IgA, low IgM and IgGNeutropenia; IUGR; NK cells very low3. Thymic defects with additional congenital anomalies  DiGeorge/velocardio-facial syndromeChromosome 22q11.2 deletion syndrome (22q11.2DS)*Large deletion (3 Mb) typically in chromosome 22 (TBX1)*AD602054Decreased or normal, 5% have low TRECs at NBS and \< 1500 CD3T cells/μL in neonatal periodNormalNormal or decreasedHypoparathyroidism; conotruncal cardiac malformation, velopalatal insufficiency; abnormal facies; intellectual disability  DiGeorge/velocardio-facial syndromeUnknownSporadicDecreased or normal  TBX1 deficiency*TBX1*AD602054Decreased or normal, may have low TRECs at NBS  CHARGE syndrome*CHD7*AD608892Decreased or normal, may have low TRECs at NBS; response to PHA may be decreasedNormalNormal or decreasedColoboma of eye; heart anomaly; choanal atresia; intellectual disability; genital and ear anomalies, CNS malformation; some are SCID-like*SEMA3E*AD608166Unknown  Winged helix nude FOXN1 deficiency*FOXN1*AR[601705]{.ul}Very lowNormalDecreasedSevere infections; abnormal thymic epithelium, immunodeficiency; congenital alopecia, nail dystrophy; neural tube defect  FOXN1 haploinsufficiency*FOXN1*AD600838Severe T cell lymphopenia at birth, normalised by adulthoodNormal/lowNot assessedRecurrent, viral and bacterial respiratory tract infections; skin involvement (eczema, dermatitis), nail dystrophy  Chromosome 10p13-p14 deletion syndrome (10p13-p14DS)*Del10p13-p14*AD601362Normal, rarely lymphopenia and decreased lymphoproliferation to mitogens and antigens; hypoplastic thymus may be presentNormalNormalHypoparathyroidism; renal disease; deafness; growth retardation; facial dysmorphism; cardiac defects may be present; recurrent infections ±  Chromosome 11q deletion syndrome (Jacobsen syndrome)*11q23del*AD[147791]{.ul}Lymphopenia; low NK cellsDecreased B cells and switched memory B cellsHypogammaglobulinemia, decreased antibody responsesRecurrent respiratory infections; multiple warts; facial dysmorphism, growth retardation4. Immuno-osseous dysplasias  Cartilage hair hypoplasia (CHH)*RMRP*AR157660Varies from severely decreased (SCID) to normal; impaired lymphocyte proliferationNormalNormal or reduced, antibodies variably decreasedShort-limbed dwarfism with metaphyseal dysostosis; sparse hair; bone marrow failure; autoimmunity; susceptibility to lymphoma and other cancers; impaired spermatogenesis; neuronal dysplasia of the intestine  Schimke immuno-osseous dysplasia*SMARCAL1*AR606622DecreasedNormalNormalShort stature, spondiloepiphyseal dysplasia, intrauterine growth retardation; nephropathy; bacterial, viral, fungal infections; may present as SCID; bone marrow failure  MYSM1 deficiency*MYSM1*AR612176T cell lymphopenia, reduced naïve T cells, low NK cellsB cell deficiencyHypogammaglobulinemiaShort stature; recurrent infections; congenital bone marrow failure, myelodysplasia; immunodeficiency affecting B cells and granulocytes; skeletal anomalies; cataracts; developmental delay  MOPD1 deficiency (Roifman syndrome)*RNU4ATAC*AR601428Decreased NK cell functionDecreased total and memory B cellsHypogammaglobulinemia, variably decreased specific antibodiesRecurrent bacterial infections; lymphadenopathy; spondyloepiphyseal dysplasia, extreme intrauterine growth retardation; retinal dystrophy; facial dysmorphism; may present with microcephaly; short stature  Immunoskeletal dysplasia with neurodevelopmental abnormalities (EXTL3 deficiency)*EXTL3*AR[617425]{.ul}DecreasedNormalDecreased to normalShort stature; cervical spinal stenosis, neurodevelopmental impairment; eosinophilia; may have early infant mortality5. Hyper IgE syndromes (HIES)  AD-HIES STAT3 deficiency (Job syndrome)*STAT3*AD LOF (dominant negative)[147060]{.ul}Normal overall; Th17, T follicular helper, MAIT, NKT cells decreased, Tregs may be increased; impaired responses to STAT3-activatng cytokinesNormal, reduced memory B cells, BAFF expression increased, impaired responses to STAT3-activating cytokinesVery high IgE, specific antibody production decreasedDistinctive facial features (broad nasal bridge); bacterial infections (boils, pulmonary abscesses, pneumatoceles) due to *S. aureus*, pulmonary aspergillus, *Pneumocystis jirovecii*; eczema, mucocutaneous candidiasis; hyperextensible joints, osteoporosis and bone fractures, scoliosis, retained primary teeth; coronary and cerebral aneurysms  IL6 receptor deficiency*IL6R*AR[147880]{.ul}Normal/increased; normal responses to mitogensNormal total and memory B; reduced switched memory BNormal/low serum IgM, G, A. Very high IgE; specific antibody production lowRecurrent pyogenic infections, cold abscesses; high circulating IL-6 levels  IL6 signal transducer (IL6ST) deficiency*IL6ST*AR[618523]{.ul}Decreased Th17 cellsReduced switched and non-switched memory B cellsHigh IgE, specific antibody production variably affectedBacterial infections, boils, eczema, pulmonary abscesses, pneumatoceles; bone fractures; scoliosis; retention of primary teeth; craniosynostosis  ZNF341 deficiencyAR-HIES*ZNF341*AR618282Decreased Th17 and NK cellsNormal, reduced memory B cells, impaired responses to STAT3-activaitng cytokinesHigh IgE and IgG, specific antibody production decreasedPhenocopy of AD-HIES; mild facial dysmorphism; early onset eczema, MCC, bacterial skin infections, abscesses, recurrent bacterial respiratory infections (S. aureus), lung abscesses and pneumatoceles; hyperextensible joints; bone fractures and retention of primary teethERBIN deficiency*ERBB2IP*AD[606944]{.ul}Increased circulating TregNormalModerately increased IgERecurrent respiratory infections, susceptibility to S. aureus, eczema; hyperextensible joints, scoliosis; arterial dilatation in some patientsLoeys-Dietz syndrome (TGFBR deficiency)*TGFBR1*AD609192NormalNormalElevated IgERecurrent respiratory infectons; eczema, food allergies; hyper-extensible joints, scoliosis, retention of primary teeths; aortic aneurisms.*TGFBR2*[610168]{.ul}Comel-Netherton syndrome*SPINK5*AR605010NormalLow switched and non-switched B cellsHigh IgE and IgA, Antibody variably decreasedCongenital ichthyosis, bamboo hair, atopic diathesis; increased bacterial infections; failure to thrivePGM3 deficiency*PGM3*AR172100CD8 and CD4 T cells may be decreasedLow B and memory B cellsNormal or elevated IgG and IgA, most with high IgE, eosinophiliaSevere atopy; autoimmunity; bacterial and viral infections; skeletal anomalies/dysplasia: short stature, brachydactyly, dysmorphic facial features; intellectual disability and cognitive impairment, delayed CNS myelination in some affected individuals  CARD11 deficiency (heterozygous DN)*CARD11*AD LOF[617638]{.ul}Normal overall, but defective T cell activation and proliferation; skewing toward Th2Normal to lowHigh IgE, poor specific antibody production; impaired activation of both NF-κB and mTORC1 pathwaysVariable atopy, eczema, food allergies, eosinophilia; cutaneous viral infections, recurrent respiratory infections; lymphoma; CID6. Defects of vitamin B12 and folate metabolism  Transcobalamin 2 deficiency*TCN2*AR613441NormalVariableDecreasedMegaloblastic anemia, pancytopenia; if untreated (B12) for prolonged periods results in intellectual disability  SLC46A1/PCFT deficiency causing hereditary folate malabsorption*SLC46A1*AR229050Variable numbers and activation profileVariableDecreasedMegaloblastic anemia, failure to thrive; if untreated for prolonged periods results in intellectual disability  Methylene-tetrahydrofolate dehydrogenase 1 (MTHFD1) deficiency*MTHFD1*AR172460Low thymic output, normal in vitro proliferationLowDecreased/poor antibody responses to conjugated polysaccharide antigensRecurrent bacterial infection, *Pneumocystis jirovecii;* megaloblastic anemia; failure to thrive; neutropenia; seizures, intellectual disability; folate-responsive7. Anhidrotic ectodermodysplasia with immunodeficiency (EDA-ID)  EDA-ID due to NEMO/IKBKG deficiency (ectodermal dysplasia, immune deficiency)*IKBKG*XL300248Normal or decreased, TCR activation impairedNormal; Low memory and isotype switched B cellsDecreased, some with elevated IgA, IgM, poor specific antibody responses, absent antibodies to polysaccharide antigensAnhidrotic ectodermal dysplasia (in some); various infections (bacteria, mycobacteria, viruses, fungi); colitis; conical teeth, variable defects of skin, hair and teeth; monocyte dysfunction  EDA-ID due to IKBA GOF mutation*NFKBIA*AD GOF164008Normal total T cells, TCR activation impairedNormal B cell numbers, impaired BCR activation, low memory and isotype switched B cellsDecreased IgG and IgA, elevated IgM, poor specific antibody responses, absent antibody to polysaccharide antigensAnhidrotic ectodermal dysplasia; various infections (bacteria, mycobacteria, viruses, fungi); colitis; variable defects of skin, hair and teeth; T cell and monocyte dysfunction  EDA-ID due to IKBKB GOF mutation*IKBKB*AD GOF[618204]{.ul}Decreased T cells, impaired TCR activationNormal number, poor functionReducedRecurrent bacterial, viral, fungal infections; variable ectodermal defects8. Calcium channel defectsORAI-1 deficiency*ORAI1*AR610277Normal, defective TCR mediated activationNormalNormalAutoimmunity; EDA; non-progressive myopathySTIM1 deficiency*STIM1*AR6059219. Other defects  Purine nucleoside phosphorylase (PNP) deficiency*PNP*AR164050Progressive decreaseNormalNormal or lowAutoimmune hemolytic anemia; neurological impairment  Immunodeficiency with multiple intestinal atresias*TTC7A*AR609332Variable, but sometimes absent or low TRECs at NBS; may have SCID phenotype at birthNormal or lowMarkedly decreased IgG, IgM, IgABacterial (sepsis), fungal, viral infections; multiple intestinal atresias, often with intrauterine polyhydramnios and early demise  Tricho-Hepato-Enteric Syndrome (THES)*TTC37*AR222470Impaired IFNγ productionVariably low numbers of switched memory B cellsHypogammaglobulinemia, may have low antibody responsesRespiratory infections; IUGR; facial dysmorphic features, wooly hair; early onset intractable diarrhea, liver cirrhosis; platelet abnormalities*SKIV2L*614602  Hepatic veno-occlusive disease with immunodeficiency (VODI)*SP110*AR604457Normal (decreased memory T cells)Normal (decreased memory B cells)Decreased IgG, IgA, IgM, absent germinal center and tissue plasma cellsHepatic veno-occlusive disease; susceptibility to *Pneumocystis jirovecii* pneumonia, CMV, candida; thrombocytopenia; hepatosplenomegaly; cerebrospinal leukodystrophy  BCL11B deficiency*BCL11B*AD617237Low, poor proliferationNormalNormalCongenital abnormalities, neonatal teeth, dysmorphic facies; absent corpus callosum, neurocognitive deficits  EPG5 deficiency (Vici syndrome)*EPG5*AR615068Profound depletion of CD4+ cellsDefectiveDecreased (particularly IgG2)Agenesis of the corpus callosum; cataracts; cardiomyopathy; skin hypopigmentation; intellectual disability; microcephaly; recurrent infections, chronic mucocutaneous candidiasis  HOIL1 deficiency*RBCK1*AR610924Normal numbersNormal, decreased memory B cellsPoor antibody responses to polysaccharidesBacterial infections; autoinflammation; amylopectinosis  HOIP deficiency*RNF31*AR612487Normal numbersNormal, decreased memory B cellsdecreasedBacterial infections; autoinflammation; amylopectinosis; lymphangiectasia  Hennekam-lymphangiectasia-lymphedema syndrome*CCBE1*AR612753Low/variableLow/variabledecreasedLymphangiectasia and lymphedema with facial abnormalities and other dysmorphic features*FAT4*AR[612411]{.ul}Low/variableLow/variabledecreasedLymphangiectasia and lymphedema with facial abnormalities and other dysmorphic features  Activating de novo mutations in nuclear factor, erythroid 2- like (NFE2L2)*NFE2L2*AD[617744]{.ul}Not reportedDecreased switched memory B cellsHypogammaglobulinemia, decreased antibody responsesRecurrent respiratory and skin infections; growth retardation, developmental delay; white matter cerebral lesions; increased level of homocysteine; increased expression of stress response genes  STAT5b deficiency*STAT5B*AR245590Modestly decreased, reduced Treg number and functionNormalhypergammaglobulinemia, increased IgEGrowth-hormone insensitive dwarfism; dysmorphic features; eczema; lymphocytic interstitial pneumonitis; prominent autoimmunity  STAT5b deficiency*STAT5B*AD (dominant negative)604260NormalNormalIncreased IgEGrowth-failure; eczema (no immune defects compared to AR STAT5 deficiency)  Kabuki syndrome (type 1 and 2)*KMT2D*AD602113NormalNormalLow IgA and occasionally low IgGTypical facial abnormalities, cleft or high arched palate, skeletal abnormalities, short stature; intellectual disability; congenital heart defects; recurrent infections (otitis media, pneumonia) in 50% of patients; autoimmunity may be present*KDM6A*XL (females may be affected)300128  KMT2A deficiency (Wiedemann-Steiner syndrome)*KMT2A*AD[605130]{.ul}NormalDecreased switched and non-switched memory B cellsHypogammaglobulinemia, decreased antibody responsesRespiratory infections; short stature; hypertelorism; hairy elbows; developmental delay, intellectual disabilityTotal number of disorders in Table 2: 58Total number of mutant genes in Table 2: 62New inborn errors of immunity: 12; *LIG1* \[[@CR30]\]; *FOXN1* haploinsufficiency \[[@CR31]\]; *IL6R* \[[@CR32], [@CR33]\]; *IL6ST* \[[@CR34], [@CR35]\]; *ZNF341* \[[@CR36], [@CR37]\]; *ERBB2IP* \[[@CR38]\]; *TGFBR1* \[[@CR39]\]; *TGFBR2* \[[@CR39]\]; AD LOF *CARD11* \[[@CR40], [@CR41]\]; AD GOF *IKBKB* \[[@CR42]\]; *SKIV2L* \[[@CR43]\]; *NFE2L2* \[[@CR44]\]Unknown cause of DiGeorge syndrome, unknown cause of CHARGE syndrome, unknown gene(s) within 10p13--14 deletion responsible for phenotype*EDA* ectodermal dysplasia anhydrotic, *HSV* herpes simplex virus, *VZV* varicella zoster virus, *BCG* Bacillus Calmette-Guerin, *NBS* newborn screen, *TREC* T cell receptor excision circle (biomarker for low T cells used in NBS), *IUGR* interuterine growth retardationTable 3Predominantly antibody deficienciesDiseaseGenetic defectInheritanceOMIMIgAssociated features1. Severe reduction in all serum immunoglobulin isotypes with profoundly decreased or absent B cells, agammaglobulinemia  BTK deficiency, X-linked agammaglobulinemia (XLA)*BTK*XL300300All isotypes decreased in majority of patients, some patients have detectable immunoglobulinsSevere bacterial infections, normal numbers of pro-B cells  μ heavy chain deficiency*IGHM*AR147020All isotypes decreasedSevere bacterial infections, normal numbers of pro-B cells  λ5 deficiency*IGLL1*AR146770  Igα deficiency*CD79A*AR112205  Igβ deficiency*CD79B*AR147245  BLNK deficiency*BLNK*AR604515  p110δ deficiency*PIK3CD*AR[602839]{.ul}Severe bacterial infections; autoimmune complications (IBD)  p85 deficiency*PIK3R1*AR[615214]{.ul}Severe bacterial infections, cytopenias, decreased or absent pro-B cells  E47 transcription factor deficiency*TCF3*AD[616941]{.ul}Recurrent bacterial infections*TCF3*AR147141Severe, recurrent bacterial infections, failure to thrive  SLC39A7 (ZIP7) deficiency*SLC39A7*AR[601416]{.ul}Early onset infections, blistering dermatosis, failure to thrive, thrombocytopenia  Hoffman syndrome/TOP2B deficiency*TOP2B*AD[126431]{.ul}Recurrent infections, facial dysmorphism, limb anomalies2. Severe reduction in at least 2 serum immunoglobulin isotypes with normal or low number of B cells, CVID phenotype  Common variable immune deficiency with no gene defect specified (CVID)UnknownVariableLow IgG and IgA and/or IgMClinical phenotypes vary: most have recurrent infections, some have polyclonal lymphoproliferation, autoimmune cytopenias and/or granulomatous disease  Activated p110δ syndrome (APDS)*PIK3CD* GOFAD615513 (APDS1)Normal/increased IgM, reduced IgG and IgASevere bacterial infections; reduced memory B cells and increased transitional B cells, EBV ± CMV viremia, lymphadenopathy/splenomegaly, autoimmunity, lymphoproliferation, lymphoma*PIK3R1*AD616005 (APDS2)Severe bacterial infections, reduced memory B cells and increased transitional B cells, lymphadenopathy/splenomegaly, lymphoproliferation, lymphoma; developmental delay  PTEN deficiency (LOF)*PTEN*AD[158350]{.ul}Normal/DecreasedRecurrent infections, Lymphoproliferation, Autoimmunity; developmental delay  CD19 deficiency*CD19*AR107265Low IgG and IgA and/or IgMRecurrent infections, may have glomerulonephritis (CD81 mutation abolishes expression of CD19, thereby phenocopying CD19 mutations)  CD81 deficiency*CD81*AR186845Low IgG, low or normal IgA and IgM  CD20 deficiency*CD20*AR112210Low IgG, normal or elevated IgM and IgARecurrent infections  CD21 deficiency*CD21*AR120650Low IgG, impaired anti-pneumococcal responseRecurrent infections  TACI deficiency^\#^*TNFRSF13B*AR or AD604907Low IgG and IgA and/or IgMVariable clinical expression and penetrance for monoallelic variants  BAFF receptor deficiency*TNFRSF13C*AR606269Low IgG and IgM,Variable clinical expression  TWEAK deficiency*TNFSF12*AD602695Low IgM and A, lack of anti-pneumococcal antibodyPneumonia, bacterial infections, warts, thrombocytopenia. Neutropenia  TRNT1 deficiency*TRNT1*AR612907B cell deficiency and hypogammaglobulinemiacongenital sideroblastic anemia, deafness, developmental delay  NFKB1 deficiency*NFKB1*AD164011Normal or low IgG, IgA, IgM, low or normal B cells, low memory B cellsRecurrent sinopulmonary infections, COPD, EBV proliferation, autoimmune cytopenias, alopecia and autoimmune thyroiditis  NFKB2 deficiency*NFKB2*AD615577Low serum IgG, A and M; low B cell numbersRecurrent sinopulmonary infections, alopecia and endocrinopathies  IKAROS deficiency*IKZF1*AD (haploinsufficiency)603023Low IgG, IgA, IgM, low or normal B cells; B cells and Ig levels reduce with ageDecreased pro-B cells, recurrent sinopulmonary infections; increased risk of ALL, autoimmunity, CVID phenotype  IRF2BP2 deficiency*IRF2BP2*AD615332Hypogammaglobulinemia, absent IgARecurrent infections, possible autoimmunity and inflammatory disease  ATP6AP1 deficiency*ATP6AP1*XL300972Variable immunoglobulin findingsHepatopathy, leukopenia, low copper  ARHGEF1 deficiency*ARHGEF1*AR618459Hypogammaglobulinemia; lack of antibodyRecurrent infections, bronchiectasis  SH3KBP1 (CIN85) deficiency*SH3KBP1*XL300310IgM, IgG deficiency; loss of antibodySevere bacterial infections  SEC61A1 deficiency*SEC61A1*AD[609213]{.ul}HypogammaglobulinemiaSevere recurrent respiratory tract infections  RAC2 deficiency*RAC2*AR[602049]{.ul}Low IgG, IgA, IgM, low or normal B cells; reduced Ab responses following vaccinationRecurrent sinopulmonary infections, selective IgA deficiency; poststreptococcal glomerulonephritis; urticaria  Mannosyl-oligosaccharide glucosidase deficiency*MOGS*AR601336Low IgG, IgA, IgM, increased B cells; poor Ab responses following vaccinationBacterial and viral infections; severe neurologic disease; also known as congenital disorder of glycosylation type IIb (CDG-IIb)3. Severe reduction in serum IgG and IgA with normal/elevated IgM and normal numbers of B cells, hyper IgM  AID deficiency*AICDA*AR[6055258]{.ul}IgG and IgA decreased, IgM increased; normal memory B cells but lacking somatic hypermutationBacterial infections, enlarged lymph nodes and germinal centers; autoimmunityAD605257IgG absent or decreased, IgA undetected, IgM increased; normal memory B cells with intact somatic hypermutationBacterial infections, enlarged lymph nodes and germinal centers. Mutations uniquely localize to the nuclear export signal.  UNG deficiency*UNG*AR191525IgG and IgA decreased, IgM increasedEnlarged lymph nodes and germinal centers  INO80 deficiency*INO80*AR610169IgG and IgA decreased, IgM increasedSevere bacterial infections  MSH6 deficiency*MSH6*AR600678Variable IgG, defects, increased IgM in some, normal B cells, low switched memory B cells, Ig class switch recombination and somatic hypermutation defectsFamily or personal history of cancer4. Isotype, light chain, or functional deficiencies with generally normal numbers of B cells  Ig heavy chain mutations and deletionsMutation or chromosomal deletion at 14q32AROne or more IgG and/or IgA subclasses as well as IgE may be absentMay be asymptomatic  Kappa chain deficiency*IGKC*AR147200All immunoglobulins have lambda light chainAsymptomatic  Isolated IgG subclass deficiencyUnknown?Reduction in one or more IgG subclassUsually asymptomatic, a minority may have poor antibody response to specific antigens and recurrent viral/bacterial infections  IgG subclass deficiency with IgA deficiencyUnknown?Reduced IgA with decrease in one or more IgG subclassRecurrent bacterial infectionsMay be asymptomatic  Selective IgA deficiencyUnknown?Absent IgA with other isotypes normal, normal subclasses and specific antibodiesMay be asymptomatic Bacterial infections, autoimmunity mildly increased  Specific antibody deficiency with normal Ig levels and normal B cellsUnknown?NormalReduced ability to produce antibodies to specific antigens  Transient hypogammaglobulinemia of infancyUnknown?IgG and IgA decreasedNormal ability to produce antibodies to vaccine antigens, usually not associated with significant infections  CARD11 GOF*CARD11*AD GOF616452Polyclonal B cell lymphocytosis due to constitutive NF-κB activationSplenomegaly, lymphadenopathy, poor vaccine response  Selective IgM deficiencyUnknown?Absent serum IgMPneumococcal/bacterialCommon variable immunodeficiency disorders (CVID) include several clinical and laboratory phenotypes that may be caused by distinct genetic and/or environmental factors. Some patients with CVID and no known genetic defect have markedly reduced numbers of B cells as well as hypogammaglobulinemia. Identification of causal variants can assist in defining treatment. In addition to monogenic causes on this table, a small minority of patients with XLP (Table [4](#Tab4){ref-type="table"}), WHIM syndrome (Table [6](#Tab6){ref-type="table"}), ICF (Table [2](#Tab2){ref-type="table"}), VODI (Table [2](#Tab2){ref-type="table"}), thymoma with immunodeficiency (Good syndrome), or myelodysplasia are first seen by an immunologist because of recurrent infections, hypogammaglobulinemia, and normal or reduced numbers of B cellsTotal number of disorders in Table 3: 46Total number of mutant genes in Table 3: 39New disorders: 9: AR *PIK3CD* \[[@CR46]--[@CR48]\]; AR *TCF3* \[[@CR49], [@CR50]\]; *SLC39A7* \[[@CR51]\]; *TOP2B* \[[@CR52]\]; *ARHGEF1* \[[@CR53]\]; *SH3KBP1* \[[@CR54]\]; *SEC61A1* \[[@CR55]\]; *AR LOF RAC2* \[[@CR56]\]; AD *AICDAEBV* Epstein-Barr virus, *COPD* chronic obstructive pulmonary disease^\#^Heterozygous variants in *TNFRSF13B* have been detected in healthy individuals, thus such variants are likely to be disease-modifying rather than disease-causingTable 4Diseases of immune dysregulationDiseaseGenetic defectInheritanceOMIMCirculating T cellsCirculating B cellsFunctional defectAssociated features1. Familial hemophagocytic lymphohistiocytosis (FHL syndromes)  Perforin deficiency (FHL2)*PRF1*AR170280Increased activated T cellsNormalDecreased to absent NK and CTL activities cytotoxicityFever, HSM, hemophagocytic lymphohistiocytosis (HLH), cytopenias  UNC13D/Munc13--4 deficiency (FHL3)*UNC13D*AR608897Increased activated T cellsNormalDecreased to absent NK and CTL activities (cytotoxicity and/or degranulation)Fever, HSM, HLH, cytopenias,  Syntaxin 11 deficiency (FHL4)*STX11*AR605014  STXBP2/Munc18--2 deficiency (FHL5)*STXBP2*AR or AD601717  FAAP24 deficiency*FAAP24*AR610884Increased activated T cellsNormalFailure to kill autologous EBV transformed B cells. Normal NK cell functionEBV-driven lymphoproliferative disease  SLC7A7 deficiency*SLC7A7*AR222700NormalNormalHyper-inflammatory response of macrophagesNormal NK cell functionLysinuric protein intolerance, bleeding tendency, alveolar proteinosis2. FHL syndromes with hypopigmentation  Chediak-Higashi syndrome*LYST*AR606897Increased activated T cellsNormalDecreased NK and CTL activities (cytotoxicity and/or degranulation)Partial albinism, recurrent infections, fever, HSM, HLH, giant lysosomes, neutropenia, cytopenias, bleeding tendency, progressive neurological dysfunction  Griscelli syndrome, type 2*RAB27A*AR603868NormalNormalDecreased NK and CTL activities (cytotoxicity and/or degranulation)Partial albinism, fever, HSM, HLH, cytopenias  Hermansky-Pudlak syndrome, type 2*AP3B1*AR603401NormalNormalDecreased NK and CTL activities (cytotoxicity and/or degranulation)Partial albinism, recurrent infections, pulmonary fibrosis, increased bleeding, neutropenia, HLH  Hermansky-Pudlak syndrome, type 10*AP3D1*AR617050NormalNormalDecreased NK and CTL activities (cytotoxicity and/or degranulation)Oculocutaneous albinism, severe neutropenia, recurrent infections, seizures, hearing loss and neurodevelopmental delay3. Regulatory T cell defects  IPEX, immune dysregulation, polyendocrinopathy, enteropathy X-linked*FOXP3*XL300292NormalNormalLack of (and/or impaired function of) CD4^+^ CD25^+^ FOXP3^+^ regulatory T cells (Tregs)Autoimmune enteropathy, early onset diabetes, thyroiditis hemolytic anemia, thrombocytopenia, eczema, elevated IgE and IgA  CD25 deficiency*IL2RA*AR147730Normal to decreasedNormalNo CD4 + C25+ cells with impaired function of Tregs cellsLymphoproliferation, autoimmunity, impaired T cell proliferation in vitro  CD122 deficiency*IL2RB*AR618495Increased memory CD8 T cells, decreased TregsIncreased memory B cellsDiminished IL2Rβ expression, dysregulated signaling in response to IL-2/IL-15; increased immature NK cellsLymphoproliferation, lymphadenopathy, hepatosplenomegaly, autoimmune hemolytic anemia, dermatitis, enteropathy, hypergammaglobulinemia, recurrent viral (EBV, CMV) infections  CTLA4 haploinsufficiency (ALPS-V)*CTLA4*AD123890DecreasedDecreasedImpaired function of Tregs.Autoimmune cytopenias, enteropathy, interstitial lung disease, extra-lymphoid lymphocytic infiltration, recurrent infections  LRBA deficiency*LRBA*AR606453Normal or decreased CD4 numbers T cell dysregulationLow or normal numbers of B cellsReduced IgG and IgA in mostRecurrent infections, inflammatory bowel disease, autoimmunity  DEF6 deficiency*DEF6*AR610094Mild CD4 and CD8 lymphopeniaLow or normal numbers of B cellsImpaired Treg functionEnteropathy, hepatosplenomegaly, cardiomyopathy, recurrent infections  STAT3 GOF mutation*STAT3*AD GOF102582DecreasedDecreasedEnhanced STAT3 signaling, leading to increased Th17 cell differentiation, lymphoproliferation and autoimmunity. Decreased Tregs and impaired functionLymphoproliferation, solid organ autoimmunity, recurrent infections  BACH2 deficiency*BACH2*AD605394Progressive T cell lymphopeniaImpaired memory B cell developmentHaploinsufficiency for a critical lineage specification transcription factorLymphocytic colitis, sinopulmonary infections  FERMT1 deficiency*FERMT1*AR[173650]{.ul}NormalNormalIntracellular accumulation of IgG, IgM, IgA, and C3 in colloid bodies under the basement membraneDermatosis characterized by congenital blistering, skin atrophy, photosensitivity, skin fragility, and scaling4. Autoimmunity with or without lymphoproliferation  APECED (APS-1), autoimmune polyendocrinopathy with candidiasis and ectodermal dystrophy*AIRE*AR or AD240300NormalNormalAIRE serves as check-point in the thymus for negative selection of autoreactive T cells and for generation of TregsAutoimmunity: hypoparathyroidism, hypothyroidism, adrenal insufficiency, diabetes, gonadal dysfunction and other endocrine abnormalities; dental enamel hypoplasia, alopecia areata enteropathy, pernicious anemia; chronic mucocutaneous candidiasis  ITCH deficiency*ITCH*AR606409Not assessedNot assessedItch deficiency may cause immune dysregulation by affecting both anergy induction in auto-reactive effector T cells and generation of TregsEarly-onset chronic lung disease (interstitial pneumonitis), autoimmunity (thyroiditis, type I diabetes, chronic diarrhea/enteropathy, and hepatitis), failure to thrive, developmental delay, dysmorphic facial features  Tripeptidyl-peptidase II deficiency*TPP2*AR190470DecreasedDecreasedTPP2 deficiency results in premature immunosenescence and immune dysregulationVariable lymphoproliferation, severe autoimmune cytopenias, hypergammaglobulinemia, recurrent infections  JAK1 GOF*JAK1*AD GOF147795Not assessedNot assessedHyperactive JAK1HSM, eosinophilia, eosinophilic enteritis, thyroid disease, poor growth, viral infections  Prolidase deficiency*PEPD*AR[613230]{.ul}NormalNormalPeptidase DAutoantibodies common, chronic skin ulcers, eczema, infections5. Immune dysregulation with colitis  IL-10 deficiency*IL10*AR124092NormalNormalNo functional IL-10 secretionInflammatory bowel disease (IBD), folliculitis, recurrent respiratory diseases, arthritis,  IL-10R deficiency*IL10RA*AR146933NormalNormalLeukocytes unresponsive to IL-10IBD, folliculitis, recurrent respiratory diseases, arthritis, lymphoma*IL10RB*AR123889NormalNormalLeukocytes unresponsive to IL-10, and IL-22, IL-26, IL-28A, IL-28B and IL-29  NFAT5 haploinsufficiency*NFAT5*AD604708NormalNormalDecreased memory B cells and plasmablastsIBD, recurrent sinopulmonary infections  TGFB1 deficiency*TGFB1*AR618213NormalNormalDecreased T cell proliferation in response to anti-CD3IBD, immunodeficiency, recurrent viral infections, microcephaly, and encephalopathy  RIPK1*RIPK1*AR618108ReducedNormal/reducedReduced activation of MAPK, NFkB pathways toRecurrent infections, early-onset IBD, progressive polyarthritis6. Autoimmune lymphoproliferative syndrome (ALPS, Canale-Smith syndrome)  ALPS-FAS*TNFRSF6*ADAR134637Increased TCR α/β+CD4^−^CD8^−^ double negative (DN) T cellsNormal, low memory B cellsApoptosis defect FAS mediatedSplenomegaly, adenopathies, autoimmune cytopenias, increased lymphoma risk, IgG and A normal or increased, elevated serum FasL, IL-10, vitamin B12  ALPS-FASLG*TNFSF6*AR134638Increased DN T cellsNormalApoptosis defect FASL mediatedSplenomegaly, adenopathies, autoimmune cytopenias, SLE, soluble FasL is not elevated  ALPS-Caspase10*CASP10*AD601762Increased DN T cellsNormalDefective lymphocyte apoptosisAdenopathies, splenomegaly, autoimmunity  ALPS-Caspase 8*CASP8*AR601763Slightly increased DN T cellsNormalDefective lymphocyte apoptosis and activationAdenopathies, splenomegaly, bacterial and viral infections, hypogammaglobulinemia  FADD deficiency*FADD*AR602457Increased DN T cellsNormalDefective lymphocyte apoptosisFunctional hyposplenism, bacterial and viral infections, recurrent episodes of encephalopathy and liver dysfunction7. Susceptibility to EBV and lymphoproliferative conditions  SAP deficiency (XLP1)*SH2D1A*XL300490Normal or Increased activated T cellsReduced Memory B cellsReduced NK cell and CTL cytotoxic activityClinical and immunologic features triggered by EBV infection: HLH, Lymphoproliferation, Aplastic anemia, Lymphoma.Hypogammaglobulinemia, Absent iNKT cells  XIAP deficiency (XLP2)*XIAP*XL300079Normal or Increased activated T cells; low/normal iNK T cellsNormal or reduced Memory B cellsIncreased T cells susceptibility to apoptosis to CD95 and enhanced activation-induced cell death (AICD)EBV infection, Splenomegaly, lymphoproliferationHLH, Colitis, IBD, hepatitisLow iNKT cells  CD27 deficiency*CD27*AR615122NormalNo memory B cellshypogammaglobulinemia; poor Ab responses to some vaccines/infectionsFeatures triggered by EBV infection, HLH, aplastic anemia, low iNKT cells, B-lymphoma  CD70 deficiency*CD70*AR602840Normal number, low Treg, poor activation and functionDecreased memory B cellshypogammaglobulinemia; poor Ab responses to some vaccines/infectionsEBV susceptibility, Hodgkin lymphoma; autoimmunity in some patients  CTPS1 deficiency*CTPS1*AR615897Normal to low, but reduced activation, proliferationDecreased memory B cellsNormal/high IgG poor proliferation to antigenRecurrent/chronic bacterial and viral infections (EBV, VZV), EBV lymphoproliferation, B cell non-Hodgkin lymphoma  CD137 deficiency (41BB)*TNFRSF9*AR602250NormalNormalLow IgG, low IgA, poor responses to T cell-dependent and T cell independent antigens, decreased T cell proliferation, IFNγ secretion, cytotoxicityEBV lymphoproliferation, B cell lymphoma, chronic active EBV infection  RASGRP1 deficiency*RASGRP1*AR603962Poor activation, proliferation, motility. Reduced naïve T cellsPoor activation, proliferation, motilityNormal IgM, IgG, increased IgARecurrent pneumonia, herpesvirus infections, EBV associated lymphomaDecreased NK cell function  RLTPR deficiency*CARMIL2*AR610859Normal number, high CD4, increased naïve CD4^+^ and CD8^+^ T cells, low Treg and MAIT, poor CD28-induced functionNormal B cell numbers, reduced memory B cellsNormal to low, poor T dependent antibody responseRecurrent bacterial, fungal and mycobacterial infections, viral warts, molluscum and EBV lymphoproliferative and other malignancy, atopy  X-linked magnesium EBV and neoplasia (XMEN)*MAGT1*XL300853Low CD4 Low recent thymic emigrant cels, inverted CD4/CD8 ratio, reduced MAIT cells, poor proliferation to CD3Normal but decreased memory B cellsProgressive hypogammaglobulinemiaReduced NK cell and CTL cytotoxic activity due to impaired expression of NKG2DEBV infection, lymphoma, viral infections, respiratory and GI infectionsGlycosylation defects  PRKCD deficiency*PRKCD*AR615559NormalLow memory B cells, high CD5 B cellsApoptotic defect in B cellsRecurrent infections, EBV chronic infection, lymphoproliferation, SLE-like autoimmunity (nephrotic and antiphospholipid syndromes), low IgGTotal number of disorders in Table 4: 44Total number of mutant genes in Table 4: 45New disorders: 8; *SLC7A7* \[[@CR57]\]; *IL2RB* \[[@CR58], [@CR59]\]; *DEF6* \[[@CR60]\]; *FERMT1* \[[@CR61]\]; *TGFB1* \[[@CR62]\]; *RIPK1* \[[@CR63], [@CR64]\]; *TNFRSF9* \[[@CR46], [@CR65], [@CR66]\]; *STAT5B* AD DN \[\]*FHL* familial hemophagocytic lymphohistiocytosis, *HLH* hemophagocytic lymphohistiocytosis, *HSM* hepatosplenomegaly, *DN* double-negative, *SLE* systemic lupus erythematous, *IBD* Inflammatory bowel diseaseTable 5Congenital defects of phagocyte number or functionDiseaseGenetic defectInheritanceOMIMAffected cellsAffected functionAssociated features1. Congenital neutropenias  Elastase deficiency (Severe congential neutropenia \[SCN\] 1)*ELANE*AD130130NMyeloid differentiationSusceptibility to MDS/leukemiaSevere congenital neutropenia or cyclic neutropenia  GFI 1 deficiency (SCN2)*GFI1*AD600871NMyeloid differentiationB/T lymphopenia  HAX1 deficiency (Kostmann Disease) (SCN3)*HAX1*AR605998NMyeloid differentiationCognitive and neurological defects in patients with defects in both HAX1 isoforms, susceptibility to MDS/leukemia  G6PC3 deficiency (SCN4)*G6PC3*AR611045NMyeloid differentiation, chemotaxis, O~2~^−^ productionStructural heart defects, urogenital abnormalities, inner ear deafness, and venous angiectasias of trunks and limbs  VPS45 deficiency (SCN5)*VPS45*AR610035NMyeloid differentiation, migrationExtramedullary hematopoiesis, bone marrow fibrosis, nephromegaly  Glycogen storage disease type 1b*G6PT1*AR602671N + MMyeloid differentiation, chemotaxis, O~2~^−^ productionFasting hypoglycemia, lactic acidosis, hyperlipidemia, hepatomegaly  X-linked neutropenia/myelodysplasia*WAS*XL GOF300299NDifferentiation, mitosis. Results from GOF mutations in GTPase binding domain of WASpNeutropenia, myeloid maturation arrest, monocytopenia, variable lymphoid anomalies  P14/LAMTOR2 deficiency*LAMTOR2*AR610389N + MEndosomal biogenesisNeutropeniaHypogammaglobulinemia ↓CD8 cytotoxicity, partial albinism, growth failure  Barth Syndrome (3-Methylglutaconic aciduria type II)*TAZ*XL300394N + LMelMitochondrial functionCardiomyopathy, myopathy, growth retardation, neutropenia  Cohen syndrome*VPS13B*AR607817NMyeloid differentiationDysmorphism, mental retardation, obesity, deafness, neutropenia  Clericuzio syndrome (Poikiloderma with neutropenia)*USB1*AR613276NMyeloid differentiationRetinopathy, developmental delay, facial dysmorphisms, poikiloderma  JAGN1 deficiency*JAGN1*AR616012NMyeloid differentiationMyeloid maturation arrest, osteopenia  3-Methylglutaconic aciduria*CLPB*AR616254NMyeloid differentiationMitochondrial proteinNeurocognitive developmental aberrations, microcephaly, hypoglycemia, hypotonia, ataxia, seizures, cataracts, IUGR  G-CSF receptor deficiency*CSF3R*AR138971NStress granulopoiesis disturbed  SMARCD2 deficiency*SMARCD2*AR601736NChromatin remodeling, Myeloid differentiation and neutrophil functional defectNeutropenia, developmental aberrations, bones, hematopoietic stem cells, myelodysplasia  Specific granule deficiency*CEBPE*AR189965NTerminal maturation and global dysfunctionNeutropenia, Neutrophils with bilobed nuclei  Shwachman-Diamond Syndrome*SBDS*AR607444NNeutrophil maturation, chemotaxis, ribosomal biogenesisPancytopenia, exocrine pancreatic insufficiency, chondrodysplasia*DNAJC21*AR617052N + HSCPancytopenia, exocrine pancreatic insufficiency*EFL1*AR617941N + HSC  HYOU1 deficiency*HYOU1*AR[601746]{.ul}NUnfolded protein responseHypoglycemia, inflammatory complications  SRP54 deficiency*SRP54*AD[604857]{.ul}NProtein translocation to ER, myeloid differentiation and neutrophil functional defectNeutropenia, exocrine pancreatic insufficiency2. Defects of motility  Leukocyte adhesion deficiency type 1 (LAD1)*ITGB2*AR600065N + M +L + NKAdherence, chemotaxis, endocytosis, T/NK cytotoxicityDelayed cord separation, skin ulcers, periodontitis, leukocytosis  Leukocyte adhesion deficiency type 2 (LAD2)*SLC35C1*AR605881N + MRolling, chemotaxisMild LAD type 1 features with hh-blood group, growth retardation, developmental delay  Leukocyte adhesion deficiency type 3 (LAD3)*FERMT3*AR607901N + M +L + NKAdherence, chemotaxisLAD type 1 plus bleeding tendency  Rac2 deficiency*RAC2*AD LOF608203NAdherence, chemotaxisO~2~− productionPoor wound healing, leukocytosis  β actin deficiency*ACTB*AD102630N + MMotilityMental retardation, short stature  Localized juvenile periodontitis*FPR1*AR136537NFormylpeptide induced chemotaxisPeriodontitis only  Papillon-Lefèvre syndrome*CTSC*AR602365N + MChemotaxisPeriodontitis, palmoplantar hyperkeratosis in some patients  WDR1 deficiency*WDR1*AR[604734]{.ul}NSpreading, survival, chemotaxisMild neutropenia, poor wound healing, severe stomatitis, neutrophil nuclei herniate  Cystic fibrosis*CFTR*AR602421M onlyChemotaxisRespiratory infections, pancreatic insufficiency, elevated sweat chloride  Neutropenia with combined immune deficiency due to MKL1 deficiency*MKL1*AR[606078]{.ul}N + M + L + NKImpaired expression of cytoskeletal genesMild thrombocytopenia3. Defects of respiratory burst  X-linked chronic granulomatous disease (CGD), gp91phox*CYBB*XL306400N + MKilling (faulty O~2~− production)Infections, autoinflammatory phenotype, IBDMcLeod phenotype in patients with deletions extending into the contiguous Kell locus  Autosomal recessive CGD*CYBA*AR608508Infections, autoinflammatory phenotype*CYBC1*[618334]{.ul}*NCF1*608512*NCF2*608515*NCF4*613960  G6PD deficiency class I*G6PD*XL[305900]{.ul}NReduced O2− productionInfections4. Other non-lymphoid defectsGATA2 deficiency*GATA2*AD137295Monocytes + peripheral DCMulti lineage cytopeniasSusceptibility to mycobacteria, HPV, histoplasmosis, alveolar proteinosis, MDS/AML/CMML, lymphedemaPulmonary alveolar proteinosis*CSF2RA*XL (Biallelic mutations in pseudo-autosomal gene)[300770]{.ul}Alveolar macrophagesGM-CSF signalingAlveolar proteinosis*CSFR2B*AR614370Total number of disorders in Table 5: 34Total number of mutant genes in Table 5: 41New disorders: 3; *SRP54* \[[@CR67], [@CR68]\]; *DNAJC21* \[[@CR69]\]; *CYBC1* \[[@CR70], [@CR71]\]Removed: Cyclic neutropenia was merged with elastase deficiency*MDS* myelodysplastic syndrome, *IUGR* intrauterine growth retardation, *LAD* leukocyte adhesion deficiency, *AML* acute myelogenous leukemia, *CMML* chronic myelomonocytic leukemia, *N* neutrophil, *M* monocyte, *MEL* melanocyte, *L* lymphocyte, *NK* natural killerTable 6Defects in intrinsic and innate immunityDiseaseGenetic defectInheritanceOMIMAffected cellsAffected functionAssociated features1. Mendelian susceptibility to mycobacterial disease (MSMD)  IL-12 and IL-23 receptor β1 chain deficiency*IL12RB1*AR601604L + NKIFN-γ secretionSusceptibility to mycobacteria and *Salmonella*  IL-12p40 (IL-12 and IL-23) deficiency*IL12B*AR161561M  IL-12Rβ2 deficiency*IL12RB2*AR[601642]{.ul}L + NK  IL-23R deficiency*IL23R*AR[607562]{.ul}L + NK  IFN-γ receptor 1 deficiency*IFNGR1*AR[209950]{.ul}M + LIFN-γ binding and signalingAD[615978]{.ul}M + L  IFN-γ receptor 2 deficiency*IFNGR2*AR147569M + LIFN-γ signaling  STAT1 deficiency*STAT1*AD LOF[614892]{.ul}M + L  Macrophage gp91 phox deficiency*CYBB*XL[300645]{.ul}Macrophage onlyKilling (faulty O~2~− production)Isolated susceptibility to mycobacteria  IRF8 deficiency*IRF8*AD[614893]{.ul}M + LImpaired development of cDCs and Th1\* cellsSusceptibility to mycobacteriaAR226990MLack of circulating monocytes and DCs, reduced NK cell numbers and function reported in some patientsSusceptibility to mycobacteria and multiple other infectious agents including EBV  SPPL2a deficiency*SPPL2A*AR[608238]{.ul}M + LImpaired development of cDCs and Th1\* cellsSusceptibility to mycobacteria and *Salmonella*  Tyk2 deficiency*TYK2*AR[611521]{.ul}M + LImpaired cellular responses to IL-10, IL-12, IL-23, and type I IFNsSusceptibility to intracellular bacteria (mycobacteria, Salmonella), and viruses  P1104A TYK2 homozygosity*TYK2*AR176941LImpaired cellular responses to IL-23MSMD or tuberculosis  ISG15 deficiency*ISG15*AR147571IFNγ production defectSusceptibility to mycobacteria (BCG), brain calcification  RORγt deficiency*RORC*AR602943L + NKLack of functional RORγT protein, IFNγ production defect, complete absence of IL-17A/F-producing T cellsSusceptibility to mycobacteria and candida  JAK1 deficiency*JAK1*AR LOF[147795]{.ul}N + LReduced JAK1 activation to cytokines, Reduced IFNγ productionSusceptibility to mycobacteria and viruses, urothelial carcinoma2. Epidermodysplasia verruciformis (HPV)  EVER1 deficiency*TMC6*AR605828KeratinocytesEVER1, EVER2 and CIB1 form a complex in keratinocytesHuman papillomavirus (HPV) (group B1) infections and cancer of the skin (typical EV)  EVER2 deficiency*TMC8*605829  CIB1 deficiency*CIB1*[618267]{.ul}  WHIM (warts, hypogammaglobulinemia, infections, myelokathexis) syndrome*CXCR4*AD GOF162643LeukocytesIncreased response of the CXCR4 chemokine receptor to its ligand CXCL12 (SDF-1)Warts (HPV) infection, neutropenia, low B cell number, hypogammaglobulinemia3. Predisposition to severe viral infection  STAT1 deficiency*STAT1*AR LOF600555Leukocytes and other cellsSTAT1-dependentIFN-α/β, γ and λ responsesSevere viral infections, mycobacterial infection  STAT2 deficiency*STAT2*AR600556Leukocytes and other cellsSTAT2-dependentIFN-α/β and λ responseSevere viral infections (disseminated vaccine-strain measles)  IRF9 deficiency*IRF9*AR[147574]{.ul}\*Leukocytes and other cellsIRF9- and ISGF3-dependent IFN-α/β and λ responsesSevere influenza disease  IRF7 deficiency*IRF7*AR605047Leukocytes, plasmacytoid dendritic cells, non-hematopoietic cellsIFN-α, β and γ production and IFN-λ production  IFNAR1 deficiency*IFNAR1*AR[107450]{.ul}\*Leukocytes and other cellsIFNAR1-dependent responses to IFN-α/βSevere disease caused by Yellow Fever vaccine and Measles vaccine  IFNAR2 deficiency*IFNAR2*AR602376Broadly expressedIFNAR2-dependent responses to IFN-α/βSevere viral infections (disseminated vaccine-strain measles, HHV6)  CD16 deficiency*FCGR3A*AR146740NK cellsAltered NK cells functionSevere herpes viral infections, particularly VZV, Epstein-Barr virus (EBV), and (HPV)  MDA5 deficiency*IFIH1*AR LOF606951Broadly expressedViral recognition and IFN inductionRhinovirus and other RNA viruses  RNA polymerase III deficiency*POLR3A*AD[614258]{.ul}Leukocytes and other cellsImpaired viral recognition and IFN induction in response to VZV or poly I:CSevere VZV infection*POLR3C*AD[617454]{.ul}*POLR3F*AD[617455]{.ul}4. Herpes simplex encephalitis (HSE)  TLR3 deficiency*TLR3*AD[613002]{.ul}Central nervous system (CNS) resident cells and fibroblastsTLR3-dependent IFN-α, β and γ responseHerpes simplex virus 1 encephalitis (incomplete clinical penetrance for all etiologies listed here); severe pulmonary influenza; VZVAR  UNC93B1 deficiency*UNC93B1*AR608204UNC-93B-dependent IFN-α, β and γ responseHerpes simplex virus 1 encephalitis  TRAF3 deficiency*TRAF3*AD601896TRAF3-dependent IFN-α, β and γ response  TRIF deficiency*TICAM1*AD607601TRIF-dependent IFN-α, β and γ responseAR  TBK1 deficiency*TBK1*AD604834TBK1-dependentIFN-α, β and γ response  IRF3 deficiency*IRF3*AD616532Low IFN-α/β production in response to HSV1 and decreased IRF3 phosphorylation  DBR1 deficiency*DBR1*AR[607024]{.ul}Impaired production of anti-viral IFNsHSE of the brainstem. Other viral infections of the brainstem.5. Predisposition to invasive fungal diseasesCARD9 deficiency*CARD9*AR607212Mononuclear phagocytesCARD9 signaling pathwayInvasive candidiasis infection, deep dermatophytoses, other invasive fungal infections6. Predisposition to mucocutaneous candidiasis  IL-17RA deficiency*IL17RA*AR605461Epithelial cells, fibroblasts, mononuclear phagocytesIL-17RA signaling pathwayCMC, folliculitis  IL-17RC deficiency*IL17RC*AR610925IL-17RC signaling pathwayCMC  IL-17F deficiency*IL17F*AD606496T cellsIL-17F-containing dimersCMC, folliculitis  STAT1 GOF*STAT1*AD GOF600555T cells, B cells, monocytesGain-of-function STAT1 mutations that impair the development of IL-17-producing T cellsCMC, various fungal, bacterial and viral (HSV) infections, auto-immunity (thyroiditis, diabetes, cytopenias), enteropathy  ACT1 deficiency*TRAF3IP2*AR607043T cells, fibroblastsFibroblasts fail to respond to IL-17A and IL-17F, and their T cells to IL-17ECMC, blepharitis, folliculitis, and macroglossia7. TLR signaling pathway deficiency with bacterial susceptibility  IRAK4 deficiency*IRAK4*AR606883Lymphocytes + granulocytes+ monocytesTIR-IRAK4 signaling pathwayBacterial infections (pyogens)  MyD88 deficiency*MYD88*AR602170Lymphocytes + granulocytes + monocytesTIR-MyD88 signaling pathway  IRAK1 deficiency*IRAK1*XL[300283]{.ul}Lymphocytes + granulocytes + monocytesTIR-IRAK1 signaling pathwayBacterial infections, X-linked MECP2 deficiency-related syndrome due to a large de novo Xq28 chromosomal deletion encompassing both *MECP2* and *IRAK1*  TIRAP deficiency*TIRAP*AR614382Lymphocytes + granulocytes + monocytesTIRAP- signaling pathway, TLR1/2, TLR2/6, and TLR4 agonists were impaired in the fibroblasts and leukocytesStaphylococcal disease during childhood8. Other inborn errors of immunity related to non-hematopoietic tissues  Isolated congenital asplenia (ICA)*RPSA*AD271400No spleenRPSA encodes ribosomal protein SA, a component of the small subunit of the ribosomeBacteremia (encapsulated bacteria)*HMOX*AR[141250]{.ul}MacrophagesHO-1 regulates iron recycling and heme-dependent damage occursHemolysis, nephritis, inflammation  Trypanosomiasis*APOL1*AD603743SomaticPore forming serum proteinTrypanosomiasis  Acute liver failure due to NBAS deficiency*NBAS*AR[608025]{.ul}Somatic and hematopoieticER stressFever induces liver failure  Acute necrotizing encephalopathy  Osteopetrosis*RANBP2*AR[601181]{.ul}Ubiquitous expressionNuclear poreFever induces acute encephalopathy*CLCN7*AR[602727]{.ul}OsteoclastsSecretory lysosomesOsteopetrosis with hypocalcemia, neurologic features*SNX10*AR[614780]{.ul}Osteopetrosis with visual impairment*OSTM1*AR[607649]{.ul}Osteopetrosis with hypocalcemia, neurologic features*PLEKHM1*AR[611466]{.ul}Osteopetrosis*TCIRG1*AR[604592]{.ul}Osteopetrosis with hypocalcemia*TNFRSF11A*AR[603499]{.ul}OsteoclastogenesisOsteopetrosis*TNFSF11*AR[602642]{.ul}StromalOsteoclastogenesisOsteopetrosis with severe growth retardation  Hidradenitis suppurativa*NCSTN*AD[605254]{.ul}EpidermisNotch signaling/gamma-secretase in hair follicle regulates keratinizationVerneuil's disease/Hidradenitis suppurativa with acne*PSEN*AD[613737]{.ul}Verneuil's disease/Hidradenitis suppurative with cutaneous hyperpigmentation*PSENEN*AD613736Verneuil's disease/Hidradenitis suppurativa9. Other inborn errors of immunity related to leukocytes  IRF4 haploinsufficiency*IRF4*AD[601900]{.ul}L + MIRF4 is a pleiotropic transcription factorWhipple's disease  IL-18BP deficiency*IL18BP*AR[604113]{.ul}Leukocytes and other cellsIL-18BP neutralizes secreted IL-18Fulminant viral hepatitisTotal number of disorders in Table 6: 53Total number of mutant genes in Table 6: 64New genes: 13, *IL12RB2* \[[@CR72]\]; *IL23R* \[[@CR72]\]; *SPPL2A* \[[@CR73]\]; *TYK2 P1104A allele* \[[@CR10]\]; *CIB1* \[[@CR74]\]; *IRF9* \[[@CR75]\]; *IFNAR1* \[[@CR76]\]; *POLR3A* \[[@CR77]\]; *POLR3C* \[[@CR77]\]; *POLR3F* \[[@CR78]\]; *DBR1* \[[@CR79]\]; *IRF4* \[[@CR80]\]; *IL18BP* \[[@CR81]\]*NF-κB* nuclear factor kappa B, *TIR* Toll and Interleukin 1 receptor, *IFN* interferon, *TLR* Toll-like receptor, *MDC* myeloid dendritic cell, *CNS* central nervous system, *CMC* chronic mucocutaneous candidiasis, *HPV* human papillomavirus, *VZV* varicella zoster virus, *EBV*, Epstein-Barr virusTable 7Autoinflammatory disordersDiseaseGenetic defectInheritanceOMIMT cellsB cellsFunctional defectAssociated features1. Type 1 interferonopathies  STING-associated vasculopathy, infantile-onset (SAVI)*TMEM173*AR612374Not assessedNot assessedSTING activates both the NF-kappa-B and IRF3 transcription pathways to induce expression of IFNSkin vasculopathy, inflammatory lung disease, systemic autoinflammation and ICC, FCL  ADA2 deficiency*ADA2*AR607575Not assessedNot assessedADAs deactivate extracellular adenosine and terminate signaling through adenosine receptorsPolyarteritis nodosa, childhood-onset, early-onset recurrent ischemic stroke and fever; some patients develop hypogammaglobulinemia  TREX1 deficiency, Aicardi-Goutieres syndrome 1 (AGS1)*TREX1*AR606609Not assessedNot assessedIntracellular accumulation of abnormal ss DNA species leading to increased type I IFN productionClassical AGS, SLE, FCL  RNASEH2B deficiency, AGS2*RNASEH2B*AR610326Not assessedNot assessedIntracellular accumulation of abnormal RNA-DNA hybrid species leading to increased type I IFN productionClassical AGS, SP  RNASEH2C deficiency, AGS3*RNASEH2C*AR610330Not assessedNot assessedClassical AGS  RNASEH2A deficiency, AGS4*RNASEH2A*AR606034Not assessedNot assessedClassical AGS  SAMHD1 deficiency, AGS5*SAMHD1*AR606754Not assessedNot assessedControls dNTPs in the cytosol, failure of which leads to increased type I IFN productionClassical AGS, FCL  ADAR1 deficiency, AGS6*ADAR1*AR146920Not assessedNot assessedCatalyzes the deamination of adenosine to inosine in dsRNA substrates, failure of which leads to increased type I IFN productionClassical AGS, BSN, SP  Aicardi-Goutieres syndrome 7 (AGS7)*IFIH1*AD GOF[615846]{.ul}Not assessedNot assessedIFIH1 gene encodes a cytoplasmic viral RNA receptor that activates type I interferon signaling through the MAVS adaptor moleculeClassical AGS, SLE, SP, SMS  DNAse II deficiency*DNASE2*AR[126350]{.ul}Not assessedNot assessedDNAse II degrades and eliminates DNA. Loss of DNase II activity induces type I interferon signalingAGS  Pediatric systemic lupus erythematosus due to DNASE1L3 deficiency*DNASE1L3*AR614420DNASE1L3 is an endonuclease that degrades extracellular DNA. DNASE1L3 deficiency decreases clearance of apoptotic cellsVery early onset SLE, reduced complement levels, autoantibodies (dsDNA, ANCA), lupus nephritis, hypocomplementemic urticarial vasculitis syndrome  Spondyloenchondro-dysplasia with immune dysregulation (SPENCD)*ACP5*AR171640Not assessedNot assessedUpregulation of IFN through mechanism possibly relating to pDCSShort stature, SP, ICC, SLE, thrombocytopenia and autoimmune hemolytic anemia, possibly recurrent bacterial and viral infections  X-linked reticulate pigmentary disorder*POLA1*XL301220Not assessedNot assessedPOLA1 is required for synthesis of cytosolic RNA:DNA and its deficiency leads to increase production of type I interferonHyperpigmentation, characteristic facies, lung and GI involvement  USP18 deficiency*USP18*AR607057Not assessedNot assessedDefective negative regulation of ISG15 leading to increased IFNTORCH-like syndrome  OAS1 deficiency*OAS1*AD GOF164350LowIncreased interferon from recognition of RNAPulmonary alveolar proteinosis, skin rash2. Defects affecting the inflammasome  Familial Mediterranean fever*MEFV*AR LOF[249100]{.ul}Mature granulocytes, cytokine-activated monocytes.Increased inflammasome-mediated induction of IL1β.Recurrent fever, serositis and inflammation responsive to colchicine. Predisposes to vasculitis and inflammatory bowel disease.AD134610Mature granulocytes, cytokine-activated monocytes.Usually M694del variant.  Mevalonate kinase deficiency (Hyper IgD syndrome)*MVK*AR[260920]{.ul}Somatic and hemaotpoieticaffecting cholesterol synthesis, pathogenesis of disease unclearPeriodic fever and leukocytosis with high IgD levels  Muckle-Wells syndrome*NLRP3*AD GOF[191900]{.ul}PMNs MonocytesDefect in cryopyrin, involved in leukocyte apoptosis and NFkB signaling and IL-1 processingUrticaria, SNHL, amyloidosis.  Familial cold autoinflammatory syndrome 1AD GOF[120100]{.ul}PMNs, monocytesNon-pruritic urticaria, arthritis, chills, fever and leukocytosis after cold exposure.  Neonatal onset multisystem inflammatory disease (NOMID) or chronic infantile neurologic cutaneous and articular syndrome (CINCA)AD GOF[607115]{.ul}PMNs, chondrocytesNeonatal onset rash, chronic meningitis, and arthropathy with fever and inflammation.  Familial cold autoinflammatory syndrome 2*NLRP12*AD GOF611762PMNs, monocytesNon-pruritic urticaria, arthritis, chills, fever and leukocytosis after cold exposure.  NLRC4-MAS (macrophage activating syndrome)*NLRC4*AD GOF616050PMNs monocytes macrophagesGain of function mutation in *NLRC4* results in elevated secretion of IL-1β and IL-18 as well as macrophage activationSevere enterocolitis and macrophage activation syndrome  Familial cold autoinflammatory syndrome 4616115  PLAID (PLCγ2 associated antibody deficiency and immune dysregulation)*PLCG2*AD GOF614878B cells, NK, Mast cellsMutations activate IL-1 pathwaysCold urticaria hypogammaglobulinemia, impaired humoral immunity, autoinflammation  Familial cold autoinflammatory syndrome 3 or APLAID (c2120A \> C)614468  NLRP1 deficiency*NLRP1*AR617388leukocytesSystemic elevation of IL-18 and caspase 1, suggesting involvement of NLRP1 inflammasomeDyskeratosis, autoimmunity and arthritis  NLRP1 GOF*NLRP1*AD GOF[615225]{.ul}KeratinocytesIncreased IL1βPalmoplantar carcinoma, corneal scarring; recurrent respiratory papillomatosis3. Non-inflammasome-related conditions  TNF receptor-associated periodic syndrome (TRAPS)*TNFRSF1A*AD142680PMNs, monocytesMutations of 55-kD TNF receptor leading to intracellular receptor retention or diminished soluble cytokine receptor available to bind TNFRecurrent fever, serositis, rash, and ocular or joint inflammation  Pyogenic sterile arthritis, pyoderma gangrenosum, acne (PAPA) syndrome, hyperzincemia and hypercalprotectinemia*PSTPIP1*AD604416Hematopoietic tissues, upregulated in activated T cellsDisordered actin reorganization leading to compromised physiologic signaling during inflammatory responseDestructive arthritis, inflammatory skin rash, myositis  Blau syndrome*NOD2*AD186580MonocytesMutations in nucleotide binding site of CARD15, possibly disrupting interactions with lipopolysaccharides and NF-kB signalingUveitis, granulomatous synovitis, camptodactyly, rash and cranial neuropathies, 30% develop Crohn colitis  ADAM17 deficiency*ADAM17*AR614328Leukocytes and epithelial cellsDefective TNFα productionEarly onset diarrhea and skin lesions  Chronic recurrent multifocal osteomyelitis and congenital dyserythropoietic anemia (Majeed syndrome)*LPIN2*AR609628Neutrophils, bone marrow cellsUndefinedChronic recurrent multifocal osteomyelitis, transfusion-dependent anemia, cutaneous inflammatory disorders  DIRA (Deficiency of the Interleukin 1 Receptor Antagonist)*IL1RN*AR612852PMNs, MonocytesMutations in the IL1 receptor antagonist allow unopposed action of Interleukin 1Neonatal onset of sterile multifocal osteomyelitis, periostitis and pustulosis.  DITRA (Deficiency of IL-36 receptor antagonist)*IL36RN*AR614204Keratinocytes, leukocytesMutations in IL-36RN leads to increase IL-8 productionPustular psoriasis  SLC29A3 mutation*SLC29A3*AR602782Leukocytes, bone cells--Hyperpigmentation hypertrichosis, histiocytosis-lymphadenopathy plus syndrome  CAMPS (CARD14 mediated psoriasis)*CARD14*AD602723Mainly in keratinocytesMutations in CARD14 activate the NF-*k*B pathway and production of IL-8Psoriasis  Cherubism*SH3BP2*AD118400Stroma cells, bone cellsHyperactived macrophage and increase NF-kBBone degeneration in jaws  CANDLE (chronic atypical neutrophilic dermatitis with lipodystrophy)*PSMB8\**AR and AD256040Keratinocytes, B cell adipose cellsMutations cause increased IFN signaling through an undefined mechanismContractures, panniculitis, ICC, fevers*PSMG2*AR609702LymphocytesPanniculitis, lipodystrophy, autoimmune hemolytic anemia  COPA defect*COPA*AD6011924PMN and tissue specific cellsDefective intracellular transport via the coat protein complex I (COPI)Autoimmune inflammatory arthritis and interstitial lung disease with Th17 dysregulation and autoantibody production  Otulipenia/ORAS*OTULIN*AR615712LeukocytesIncrease LUBAC induction of NF-KB activation leading to high proinflamatory cytokines levels.Fever, diarrhea, dermatitis  A20 deficiency*TNFAIP3*AD616744LymphocytesDefective inhibition of NF-KB signaling pathwayArthralgia, mucosal ulcers, ocular inflammation  AP1S3 deficiency*AP1S3*AR[615781]{.ul}KeratinocytesDisrupted TLR3 translocationPustular psoriasis  ALPI deficiency*ALPI*AR171740Intestinal epithelial cellsDeficient inhibition of LPS in intestineInflammatory bowel disease  TRIM22*TRIM22*AR606559Macrophages, intestinal epithelial cellsGranulomatous colitisInflammatory bowel disease  T cell lymphoma subcutaneous panniculitis-like (TIM3 deficiency)*HAVCR2*AR[618398]{.ul}LeukocytesIncreased inflammasome activity due to defective checkpoint signalingPanniculitis, HLH, polyclonal cutaneous T cell infiltrates or T cell lymphomaTotal number of disorders in Table 7: 45Total number of mutant genes in Table 7: 42New disorders: 9; *DNASE2* \[[@CR82]\]; *DNASE1L3* \[[@CR83]--[@CR85]\]; *OAS1* \[[@CR86]\]; AD *MEFV; NLRP1 GOF* \[[@CR87], [@CR88]\]; *ALPI* \[[@CR89]\]; *TRIM22* \[[@CR90]\]; *PSMG2* \[[@CR91]\]; *HAVCR2* \[[@CR92], [@CR93]\]*IFN* interferon, *HSM* hepatosplenomegaly, *CSF* cerebrospinal fluid, *SLE* systemic lupus erythematosus, *TORCH* toxoplasmosis, other, rubella, cytomegalovirus, and herpes infections, *SNHL* sensorineural hearing loss, *AGS* Aicardi-Goutières syndrome, *BSN* bilateral striatal necrosis, *FCL* familial chilblain lupus, *ICC* intracranial calcification, *IFN* interferon type I, *pDCs* plasmacytoid dendritic cells, *SP* spastic paraparesis, *SMS* Singleton-Merten syndrome, *ss* single-stranded DNA\*Variants in *PSMB4*, *PSMB9*, *PSMA3*, and *POMP* have been proposed to cause a similar CANDLE phenotype in compound heterozygous monogenic (*PSMB4*), digenic (*PSMA3/PSMB8*, *PSMB9/PSMB4*, *PSMB4/PSMB8*) and AD monogenic (*POMP*) models \[[@CR94]\]Table 8Complement deficienciesDiseaseGenetic defectInheritanceGene OMIMLaboratory featuresAssociated featuresComplement deficiencies  C1q deficiency due to defects*C1QA*AR120550Absent CH50 hemolytic activity, defective activation of the classical pathway, diminished clearance of apoptotic cellsSLE, infections with encapsulated organisms*C1QB*AR120570*C1QC*AR120575  C1r deficiency*C1R*AR613785Absent CH50 hemolytic activity, defective activation of the classical pathwaySLE, infections with encapsulated organisms, Ehlers-Danlos phenotype  C1r Periodontal Ehlers-Danlos*C1R*AD GOF613785Normal CH50Hyperpigmentation, skin fragility  C1s deficiency*C1S*AR613785Absent CH50 hemolytic activity, defective activation of the classical pathwaySLE, infections with encapsulated organisms, Ehlers-Danlos phenotype  C1s Periodontal Ehlers-Danlos*C1S*AD GOF613785Normal CH50Hyperpigmentation, skin fragility  Complete C4 deficiency*C4A + C4B*AR120810Absent CH50 hemolytic activity, defective activation of the classical pathway, complete deficiency requires biallelic mutations/deletions/conversions of both C4A and C4BSLE, infections with encapsulated organisms, partial deficiency is common (either C4A or C4B) and appears to have a modest effect on host defense  C2 deficiency*C2*AR217000Absent CH50 hemolytic activity, defective activation of the classical pathwaySLE, infections with encapsulated organisms, atherosclerosis  C3 deficiency (LOF)*C3*AR120700Absent CH50 and AH50 hemolytic activity, defective opsonization, defective humoral immune responseInfections, glomerulonephritis, atypical hemolytic-uremic syndrome with GOF mutations.  C3 GOF*C3*AD GOF120700Increased activation of complementAtypical hemolytic-uremic syndrome  C5 deficiency*C5*AR120900Absent CH50 and AH50 hemolytic activityDefective bactericidal activityDisseminated neisserial infections  C6 deficiency*C6*AR217050Absent CH50 and AH50 hemolytic activity, defective bactericidal activity  C7 deficiency*C7*AR217070  C8α deficiency*C8A*AR120950  C8 γ deficiency*C8G*AR120930  C8 β deficiency*C8B*AR120960  C9 deficiency*C9*AR120940Reduced CH50 and AP50 hemolytic activity, deficient bactericidal activityMild susceptibility to disseminated neisserial infections  MASP2 deficiency*MASP2*AR605102Deficient activation of the lectin activation pathwayPyogenic infections, inflammatory lung disease, autoimmunity  Ficolin 3 deficiency*FCN3*AR604973Absence of complement activation by the Ficolin 3 pathway.Respiratory infections, abscesses  C1 inhibitor deficiency*SERPING1*AD606860Spontaneous activation of the complement pathway with consumption of C4/C2, spontaneous activation of the contact system with generation of bradykinin from high molecular weight kininogenHereditary angioedema  Factor B GOF*CFB*AD GOF[612924]{.ul}Gain-of-function mutation with increased spontaneous AH50Atypical hemolytic-uremic syndrome  Factor B deficiency*CFB*AR[615561]{.ul}Deficient activation of the alternative pathwayInfections with encapsulated organisms  Factor D deficiency*CFD*AR134350Absent AH50 hemolytic activityNeisserial infections  Properdin deficiency*CFP*XL300383Absent AH50 hemolytic activityNeisserial infections  Factor I deficiency*CFI*AR217030Spontaneous activation of the alternative complement pathway with consumption of C3Infections, disseminated neisserial infections, atypical Hemolytic-uremic syndrome, preeclampsia  Factor H deficiency*CFH*AR or AD134370Spontaneous activation of the alternative complement pathway with consumption of C3  Factor H-related protein deficiencies*CFHR1*AR or AD134371,Normal CH50, AH50, autoantibodies to Factor H., linked deletions of one or more CFHR genes leads to susceptibility autoantibody-mediated aHUSOlder onset atypical hemolytic-uremic syndrome, disseminated neisserial infections*CFHR2*600889,*CFHR3*605336,*CFHR4*605337,*CFHR5*608593  Thrombomodulin deficiency*THBD*AD188040Normal CH50, AH50Atypical hemolytic-uremic syndrome  Membrane Cofactor Protein (CD46) deficiency*CD46*AD120920Inhibitor of complement alternate pathway, decreased C3b bindingAtypical hemolytic-uremic syndrome, infections, preeclampsia  Membrane Attack Complex Inhibitor (CD59) deficiency*CD59*AR107271Erythrocytes highly susceptible to complement-mediated lysisHemolytic anemia, polyneuropathy  CD55 deficiency (CHAPEL disease)*CD55*AR125240Hyperactivation of complement on endotheliumProtein losing enteropathy, thrombosisTotal number of disorders in Table 8: 30Total number of mutant genes in Table 8: 36New disorders: 2; *C1S* AD GOF \[[@CR95]\], *C1R* AD GOF \[[@CR95]\]*MAC* membrane attack complex, *SLE* systemic lupus erythematosusTable 9Bone marrow failureDiseaseGenetic defectInheritanceGene OMIMT cellsB cellsOther affected cellsAssociated features**Major CategorySubcategory**Bone marrow failureFanconi anemia type A*FANCA*AR[227650]{.ul}Normal to lowNormal to lowHSCNormal to low NK, CNS, skeletal, skin, cardiac, GI, urogenital anomalies, increased chromosomal breakageBone marrow failure with immune deficiencyFanconi AnemiaFanconi anemia type B*FANCB*XLR[300514]{.ul}Fanconi anemia type C*FANCC*AR[227645]{.ul}Fanconi anemia type D1*BRCA2*AR605724Fanconi anemia type D2*FANCD2*AR[227646]{.ul}Fanconi anemia type E*FANCE*AR[600901]{.ul}Fanconi anemia type F*FANCF*AR[603467]{.ul}Fanconi anemia type G*XRCC9*AR[614082]{.ul}Fanconi anemia type I*FANCI*AR[609053]{.ul}Fanconi anemia type J*BRIP1*AR[609054]{.ul}Fanconi anemia type L*FANCL*AR[614083]{.ul}Fanconi anemia type M*FANCM*AR[618096]{.ul}Fanconi anemia type N*PALB2*AR[610832]{.ul}Fanconi anemia type O*RAD51C*AR[613390]{.ul}Fanconi anemia type P*SLX4*AR[613951]{.ul}Fanconi anemia type Q*ERCC4*AR[615272]{.ul}Fanconi anemia type R*RAD51*AR[617244]{.ul}Fanconi anemia type S*BRCA1*AR[617883]{.ul}Fanconi anemia type T*UBE2T*AR[616435]{.ul}Fanconi anemia type U*XRCC2*AR[617247]{.ul}Fanconi anemia type V*MAD2L2*AR[617243]{.ul}Fanconi anemia type W*RFWD3*AR[617784]{.ul}MIRAGE (myelodysplasia, infection, restriction of growth, adrenal hypoplasia, genital phenotypes, enteropathy)*SAMD9*AD GOF[617053]{.ul}Not reportedNot reportedHSC, myeloid cellsIntrauterine growth retardation, gonadal abnormalities, adrenal failure, MDS with chromosome 7 aberrations, predisposition to infections, enteropathy, absent spleenAtaxia pancytopenia syndrome*SAMD9L*AD GOF[611170]{.ul}NormalLowHSC, myeloid cellsMDS, neurological featuresDKCX1*DKC1*XL[305000]{.ul}Normal to lowNormal to lowHSCBone marrow failure, pulmonary and hepatic fibrosis, nail dystrophy, leukoplakia, reticulate skin pigmentation; microcephaly, neurodevelopmental delayDyskeratosis CongenitaDKCA1*TERC*AD[127550]{.ul}DKCA2*TERT*AD[187270]{.ul}DKCA3*TINF2*AD[604319]{.ul}DKCA4*RTEL1*AD616373DKCA5*TINF2*AD[268130]{.ul}DKCA6*ACD*AD[616553]{.ul}DKCB1*NOLA3*AR[224230]{.ul}DKCB2*NOLA2*AR[613987]{.ul}DKCB3*WRAP53*AR[613988]{.ul}DKCB4*TERT*AR[613989]{.ul}DKCB5*RTEL1*AR[615190]{.ul}LowNail dystrophy, leukoplakia, bone marrow failure, severe B cell immunodeficiency, intrauterine growth retardation, growth retardation, microcephaly, cerebellar hypoplasia, and esophageal dysfunctionDKCB6*PARN*AR[616353]{.ul}Normal to lowDevelopmental delay, microcephaly, and cerebellar hypoplasiaDKCB7*ACD*AR[616553]{.ul}Normal to lowBone marrow failure, pulmonary and hepatic fibrosis, nail dystrophy, leukoplakia, reticulate skin pigmentation; microcephaly, neurodevelopmental delayBMFS1 (SRP72-deficiency)*SRP72*AD[602122]{.ul}NANABone marrow failure and congenital nerve deafnessBMFS2*ERCC6L2*AR[615667]{.ul}NANABone marrow failure, learning difficulties, microcephalyBMFS5*TP53*AD[618165]{.ul}NALow BErythroid hypoplasia, B cell deficiencyCoats plus syndrome*STN1*AR[613129]{.ul}NormalNormalIntrauterine growth retardation, premature aging, pancytopenia, hypocellular bone marrow, gastrointestinal hemorrhage due to vascular ectasia, intracranial calcification, abnormal telomeres*CTC1*AR[617053]{.ul}Not reportedNot reportedTotal number of disorders in Table 9: 43Total number of mutant genes in Table 9: 43*HSC* hematopoietic stem cell, *NK* natural killer, *CNS* central nervous system, *GI* gastrointestinal, *MDS* myelodysplastic syndrome, *DKCX* X-inked dyskeratosis congenital, *DKCA* autosomal dominant dyskeratosis congenita, *DKCB* autosomal recessive dyskeratosis congenita, *BMFS* bone marrow failure syndromeTable 10Phenocopies of inborn errors of immunityDiseaseGenetic defect/presumed pathogenesisCirculating T cellsCirculating B cellsSerum IgAssociated features/similar PID1. Phenocopies of inborn errors of immunityAssociated with somatic mutations  Autoimmune lymphoproliferative syndrome (ALPS--SFAS)Somatic mutation in *TNFRSF6*Increased CD4^−^CD8^−^double negative (DN) αβ T cellsNormal, but increased number of CD5+ B cellsNormal or increasedSplenomegaly, lymphadenopathy, autoimmune cytopenias, Defective lymphocyte apoptosis/ALPS--FAS (=ALPS type Im)  RAS-associated autoimmune leukoproliferative disease (RALD)Somatic mutation in *KRAS* (GOF)NormalB cell lymphocytosisNormal or increasedSplenomegaly, lymphadenopathy, autoimmune cytopenias, granulocytosis, monocytosis/ALPS-like  RAS-associated autoimmune leukoproliferative disease (RALD)Somatic mutation in *NRAS* (GOF)Increased CD4−CD8− double negative (DN) T alpha/beta cellsLymphocytosisNormal or increasedSplenomegaly, lymphadenopathy, autoantibodies/ALPS-like  Cryopyrinopathy, (Muckle-Wells/CINCA/NOMID-like syndrome)Somatic mutation in *NLRP3*NormalNormalNormalUrticaria-like rash, arthropathy, neurological signs  Hypereosinophilic syndrome due to somatic mutations in STAT5bSomatic mutation in *STAT5B* (GOF)NormalNormalNormalEosinophilia, atopic dermatitis, urticarial rash, diarrheaAssociated with autoantibodies  Chronic mucocutaneous candidiasisAutoAb to IL-17 and/or IL-22NormalNormalNormalEndocrinopathy, chronic mucocutaneous candidiasis/CMC  Adult-onset immunodeficiency with susceptibility to mycobacteriaAutoAb to IFNγDecreased naive T cellsNormalNormalMycobacterial, fungal, *Salmonella* VZV infections/MSMD, or CID  Recurrent skin infectionAutoAb to IL-6NormalNormalNormalStaphylococcal infections/STAT3 deficiency  Pulmonary alveolar proteinosisAutoAb to GM-CSFNormalNormalNormalPulmonary alveolar proteinosis, cryptococcal meningitis, disseminated nocardiosis/CSF2RA deficiency  Acquired angioedemaAutoAb to CI inhibitorNormalNormalNormalAngioedema/*C1 INH* deficiency (hereditary angioedema)  Atypical hemolytic uremic syndromeAutoAb to Complement Factor HNormalNormalNormalaHUS = Spontaneous activation of the alternative complement pathway  Thymoma with hypogammaglobulinemia (Good syndrome)AutoAb to various cytokinesIncreased CD8+ T cellsNo B cellsDecreasedInvasive bacterial, viral or opportunistic infections, autoimmunity, PRCA, lichen planus, cytopenia, colitis, chronic diarrhea*aHUS* atypical hemolytic uremic syndrome, *XL* X-linked inheritance, *AR* autosomal recessive inheritance, *AD* autosomal dominant inheritance, *LOF* loss-of-function, *GOF* gain-of-function, *PRCA* pure red cell aplasiaTotal number of conditions for Table 10: 12

The advances in our understanding of clinical immunology continue to expand at a vast and remarkable rate, with the addition in this update of many---64, distributed across all tables (Fig. [1b](#Fig1){ref-type="fig"})---novel genetic defects underlying inborn errors of immunity. Perhaps not surprisingly, most if not all of these new variants were identified by NGS, thus highlighting that whole exome/whole genome sequencing has become the gold standard for identifying novel pathogenic gene variants \[[@CR6]--[@CR8]\]. Indeed, since the first application of NGS to identify novel inborn errors of immunity was published in 2010 \[[@CR18]\], \~ 45% of all currently known disease-causing variants have been discovered by whole exome/genome sequencing. Thus, a typical approach to identifying a pathogenic variant in a new patient might now consist of first sequencing a phenotype-driven panel of genes and advancing to whole exome/genome sequencing if the cause of disease remains elusive.

In this update, we increase the list of immunological diseases to 404, with 430 known genetic defects identified as causing these conditions. The unbiased application of NGS to the discovery and characterization of novel inborn errors of immunity continues to inform clinical and basic immunology. Thus, additional phenotypes have been identified for conditions resulting from variants in known and novel genes; the penetrance of genetic variants on clinical phenotypes has been shown to be highly variable; and clinical entities sharing common phenotypes have been discovered. For example, this update includes the findings that bi-allelic mutations in *ZNF341* \[[@CR19], [@CR20]\], *IL6ST* (encoding gp130, a common component of the receptors for IL-6, IL-11, IL-27, LIF, OSM, CNTF) \[[@CR21], [@CR22]\], or *IL6R* \[[@CR23], [@CR24]\] all cause conditions that resemble autosomal dominant hyper-IgE syndrome due to dominant negative mutations in *STAT3* \[[@CR15]\]. Detailed analyses of these patients revealed a novel mechanism of regulating STAT3 signaling (via the transcription factor ZNF341) and defined the exact consequences of impaired IL-6/IL-6R/gp130 and putatively IL-11/IL-11R/gp130 signaling to the phenotype of AD-HIES.

Furthermore, key findings over the past 2 years continue to reveal that distinct mechanisms of disease (GOF, LOF, dominant negative, haploinsufficient), as well as different modes of inheritance (autosomal recessive, autosomal dominant) of variants in the *same* gene can cause disparate clinical conditions. This is a fascinating aspect of the genetics of human disease, and a salient reminder to be cognizant of the nature of the genetic variants identified from NGS. It is these genes that have several entries in this update. A few recent examples include:Heterozygous variants in *CARD11* \[[@CR25], [@CR26]\] or *STAT5B* \[[@CR27]\] can be pathogenic due to negative dominance. This was potentially unexpected because autosomal recessive LOF variants in both of these genes were previously reported to cause combined immunodeficiency and severe immune dysregulation, respectively, yet heterozygous relatives of these affected individuals were healthy \[[@CR28], [@CR29]\].While heterozygous dominant negative mutations in *TCF3*, encoding the transcription factor E47, cause B cell deficiency and agammaglobulinemia \[[@CR30]\], nonsense mutations in *TCF3* have now been identified that are pathogenic only in an autosomal recessive state, as heterozygous carriers of these particular allelic variants remained healthy \[[@CR31], [@CR32]\].A heterozygous hypermorphic variant in *IKBKB* was found to cause a combined immunodeficiency \[[@CR33]\] not too dissimilar to the original description of bi-allelic, recessive variants in *IKBKB* \[[@CR34]\]. Similarly, bi-allelic LOF mutations in *PIK3CD* are now known to cause B cell deficiency and agammaglobulinemia \[[@CR35]--[@CR37]\], which is quite distinct from the immune dysregulated state of individuals with monoallelic activating *PIK3CD* mutations \[[@CR1], [@CR37]\]. This observation nicely parallels the earlier findings of either homozygous or heterozygous mutations in *PIK3R1* that clinically phenocopy recessive or activating mutations in *PIK3CD* respectively \[[@CR1], [@CR37]\].Distinct diseases can result from heterozygous mutations in *IKZF1* (Ikaros): combined immunodeficiency due to dominant negative alleles \[[@CR38]\] or CVID due to haploinsufficiency \[[@CR39]\].Similar to *STAT1* \[[@CR40]\], variants in *RAC2* \[[@CR41]--[@CR45]\] or *CARD11* \[[@CR25], [@CR26], [@CR28]\] can be pathogenic either as monoallelic GOF or LOF or bi-allelic recessive LOF.

Thus, these findings have revealed the fundamental importance of elucidating the impact of a novel variant on the function of the encoded protein and thus the mechanism of pathogenicity. Furthermore, these new entries are an important reminder not to overlook the potential significance of identifying heterozygous variants in genes previously believed to cause disease only in a biallelic manner or to result in a previously defined specific clinical entity. Indeed, there are now at least 35 genes that have multiple entries in the current update, reflecting the distinct mechanisms by which variants result in or cause disease (e.g., *STAT1, STAT3, NLRP1, RAC2, ZAP70, CARD11, IKBKB, WAS, JAK1, IFIH1, C3*, *C1R, C1S*--GOF or LOF; *STAT5, STAT1, CARD11, ACD, CFH, CFHR1--5, FOXN1, RAC2, TCF3, AICDA, PIK3R1, IFNGR1, TREX1, TICAM1, IRF8*--AD or AR; *PIK3CD*--AD GOF, AR LOF; *IKZF1*--AD, or haploinsufficient; *NLRP3*---distinct disease phenotypes despite all resulting from GOF alleles).

As noted above, genetic, biochemical, and functional analyses of putative novel pathogenic variants need to meet stringent criteria to be considered for inclusion in this update \[[@CR17]\]. These criteria can make reporting genetic findings from single cases challenging, as often the best evidence that a novel variant is disease-causing is to identify additional, similarly affected but unrelated individuals with the same variants, or functionally similar variants in the same gene. While this can be challenging, particularly in light of the rarity of individual inborn errors of immunity, robust mechanistic laboratory investigations continue to provide compelling data from single patients, with or without evidence from animal models. Specifically, homozygous LOF mutations in *IRF9* \[[@CR46]\] and *IL18BP* \[[@CR47]\] were identified and rigorously characterized in single patients and found to be the molecular cause of life-threatening influenza and fulminant viral hepatitis, respectively.

The study and discovery of novel inborn errors of immunity can also enable improved patient management by implementing gene-specific targeted therapies. Thus, JAK inhibitors are being used to treat disorders of immune dysregulation resulting from GOF mutations in *JAK1*, *STAT1* or *STAT3* \[[@CR11]\], while mTOR inhibitors such as rapamycin or PI3K p110δ-specific inhibitors have been reported for the treatment of individuals with *PIK3CD* GOF or *PIK3R1* LOF mutations \[[@CR37]\]. Regarding novel gene defects, immune dysregulation due to *DEF6* deficiency was successfully treated with abatacept (CTLA4-Ig) \[[@CR48]\]. This correlated with impaired CTLA4 expression and function in DEF6-deficient T cells \[[@CR48]\] and parallels the therapeutic use of abatacept and belatacept for LRBA-deficiency and CTLA4 haploinsufficiency, both of which are characterized by reduced CTLA4 expression in affected regulatory T cells \[[@CR49], [@CR50]\]. From a theoretical perspective, the finding that MSMD can be caused by mutations in *IL12RB2*, *IL23R* or *SPPL2A* and that these mutations are associated with impaired production of IFNγ---a requisite of anti-mycobacterial immunity---implies that IFNγ administration could be therapeutically beneficial in these clinical settings \[[@CR51], [@CR52]\]. Similarly, recombinant IL18BP could potentially ameliorate viral-induced liver toxicity due to *IL18BP* deficiency \[[@CR47]\].

The goals of the IUIS Expert Committee on Inborn Errors of Immunity are to increase awareness, facilitate recognition, promote optimal treatment, and support research in the field of disorders of immunity. Thus, this 2019 Update and the accompanying "Phenotypical IUIS Classification" publications are intended as resources for clinicians and researchers. Importantly, these tables underpin the design of panels used for targeted gene sequencing to facilitate genetic diagnoses or inborn errors. In the past 5 years, the number of gene defects underlying inborn errors of immunity has nearly doubled from \~ 250 to 430 (Fig. [1a](#Fig1){ref-type="fig"}). The human genome contains 1800--2000 genes that are known to be involved in immune responses \[[@CR13]\]. Thus, the discovery and study of inborn errors of immunity has elegantly illustrated that \> 20% of these immune genes play non-redundant roles in host defense and immune regulation. With the improved identification and phenotyping of patients with rare diseases, combined with high throughput genome sequencing, the number of genes fundamentally required for immunity will no doubt continue to increase, further revealing critical and novel roles for specific genes, molecules, pathways and cell types in immune responses, as well as mechanisms of disease pathogenesis and targets for immunotherapies. The field of inborn errors of immunity, and the global clinical and research communities, will therefore continue to provide key insights into basic and clinical immunology.
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